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INRODUCTION 
Globally,  Sexually transmitted infections  are a major cause of 
morbidity.  The World Health Organization rec ommends  the use of 
term “ Sexually transmitted infections”(STI)  ins tead of   “  sexually 
transmitted diseases” (STD)1  because,  sexually  transmitted  
infections  may  remain symptomless  w ithout resulting  in disease or 
they may  also end in  abortive form1.  
Human Papilloma Virus  (HPV) is  one of  the most c ommon 
cause of  STI’s in the world.  Genital HPV,  the known cause of 
cervic al c anc er is  a very common sexually transmitted disease. 
Upto 70% of  genital Human Papilloma Virus (HPV) infections  are 
subc linic al.  This  Sexually Transmitted Infection,  HPV plays  a 
pivotal role in the development of  squamous  cell c arc inoma and 
adenocarc inoma of genital tract.  In latent infections, the HPV viral 
DNA c an be isolated w ith no morphologic al les ions.  Genital HPV 
infection c an be detected by c linic al examination,  histology, 
cytology or  molecular  analys is.  Genital HPV infection,  which is 




The estimated prevalence and annual inc idenc e of  treatable 
STDs by 1999 in South and Southeast As ia is  47 million.  Infected 
individuals  per  thousand populations  are 49.5.  The es timated new 
inc idence of infection per year is 150 million 1 ,2  .  
THE BURDEN OF THE DISEASE  
Cervic al c ancer ranks  third,  among the most c ommon cancer 
in w omen world w ide. The burden of the disease is  more in the 
developing countr ies.  
India has  a population of 366,580 lakhs.   Cervic al cancer is 
the mos t c ommon malignancy among w omen in India.  The age 
group at the r isk of  developing carc inoma cervix is  15 years  and 
above.  In India,  it is  stated that cervic al carc inoma has  been 
diagnosed in 134420 women every year and every year  72825 die 
due to the disease2.   Cervic al HPV infection in general population 
are estimated to be about 7.  9%.   HPVs type 16 and 18 are 
attr ibuted to 82.5% of all  invas ive  c ervical  cancer.  From s tatistics 
it is   estimated that the number of  c ervic al c anc er in 2025 w ill be 
203747  and  death w ill be 1,15,171.For one lakh population ,  the 
crude inc idenc e rate is 23.52.  
The burden of  the disease is  region spec if ic  the high rates  of 
cervic al c anc er in developing c ountr ies  are due to assoc iated r isk 
factors like,  high rate of  fertility,  early age of  bir th of  f irst child, 
inadequate know ledge and awareness.  
HPV vacc ines  and screening for  HPV infection are being 
cons idered as  very effective tools  for  cervic al cancer c ontrol.  For 
many developing countr ies  it is  diff icult to establish organized 
screening programmes.  But an effective screening for  c ervic al 
cancer can reduc e the inc idence of c ervic al c anc er upto 90%.  
Women  educ ation ,Improving s tandards  of   living ,Motivated 
health education,  along  w ith  this   early  detection  of   c ervic al  
cancers   us ing  screening  proc edures   like   cytology,  HPV  DNA  
detection and provis ion of  fac ilities  and infrastructures  for 
treatment c an control HPV infection This,  also decreases  the 
cervic al c anc er inc idence in  developing countr ies3.  
REVIEW OF LITERATURE 
 Cervical HPV infection:  
Cancer cervix is  the third most leading c anc er in female 
population in the world,  while it is  the most common cancer in 
female population in developing c ountr ies.  HPV,  DNA detection 
was used as an adjuvant for PAP screening.  
Occ urrenc e of  asymptomatic  genital HPV infections  and also 
occurrence of  HPV related anogenital cancers  are more c ommon 
among developing countr ies like India.  
In female general population,  the HPV occurrence w ith 
normal cervic al c ytology is  8%.  The occurenc e of  HPV 16 and 18 
strains    among female population w ith routine cytology is  6%4. 
Generally the prevalence of  HPV is  higher in developing countr ies 
espec ially rural India4.  
Incidence:  
The inc idence of  c ervic al c ancer vary among different 
population.  This  depends  on the HPV prevalenc e in that population 
and  other   assoc iated  cofactors  that  contr ibute to  the 
development of c ervical carc inoma.  
Cervic al c anc er accounts for  15% of all malignanc ies  in 
women all over the w orld.  Carc inoma cervix is  the major cause of 
death in women in India espec ially rural India.  In south east As ia 
20-30% of the malignanc ies are attr ibuted to carc inoma c ervix.  
Cancer cervix is  a major c ause of  death among w omen,  living 
in developing countr ies.  In 2007, the projected inc idence of c ases 
of  cancer c ervix according to national c anc er registry of  India w as 
90708 w ith f ive year  survival rate of  about 48%.  It is  estimated that 
in India 1,26,000,  new c ases occur each year5.  Only malignancy 
that can be prevented w ith primary preventive measures like 
screening and vacc ination is  the c ervic al c ancer. With the PAP 
smear screening program,  a marvellous  reduction has been observed 
in the inc idenc e and mortality of cervic al c ancer globally5.  
HPV: INDIAN SCENAIRO6  
There has  been a r is ing tendency of  genital w art infec tions  in 
the past few years  (HPV 6 & 11 are respons ible for 90% of genital 
warts).  Cervic al cancer is  the most common malignancy among 
women in India.  Approximately 500,000 women are detected 
annually all over world.  
HPV prevalenc e and  dis tr ibution in women from India  w ere 
found to be higher, espec ially in rural India5 ,6.  
Cytology/ His tology HPV Prevalenc e 
Invas ive c ervical cancer (ICC) 94.6% 
High grade squamous  
intraepithelial les ion (HSIL) 86.5% 
Low grade squamous intraepithelial 
les ions (LSIL) 65.4% 
Normal 12% 
HPV type dis tribution in women from India: 
HPV DNA  detection in squamous  c ell c arc inoma was  found 
pos itive in 99%  of   c ases.  Of these c ases, Us ing PCR technique7 
HPV types 16 and 18 are isolated in higher perc entage.  
In Indian women, it affects nearly 132,000 and death 76000 
every year.  
MOLECULAR VIROLOGY OF HUMAN PAPILLOMAVIRUS  
Human papilloma virus is a small double stranded DNA virus 
of the papova virus family. It is  a spherical virus measuring 
approximately 50nm in diameter. The genome of the virus, a 
covalently c losed circ le of super coiled DNA, is placed ins ide a non-
enveloped icosahedral caps id8. Detergents, formalin and high 
temperature, can open the viral (K) caps id and the antigen can be 
exposed. Its molecular weight is 5 X 166 Daltons. Each genome is 
made of 800 nuc leotide base pairs .The HPV  genome is  separated  
into  three  divis ions   based  on  the  function of  that  particular   
genome. The genome coding for viral proteins classif ied as ‘E’ (early)  
and ‘L’(late) proteins. The ‘E’ genes are required for  viral replication 
and the ‘L’ genes for structural proteins that form the caps id10.The  
early genes  are E1 E2  E4  E5  E 6 E 7  and  late  genes  are  L1  L2  L39. 
The  E  region  are the  genes  involved in invas ive  carc inoma  by  
interacting  with  host  cell The third non coding region, that is 
essential for regulatory  functions of  the virus proteins.10 
CULTURE CHARACTERISTICS 
HPV virus  needs  differentiating squamous  epithelium for 
their  growth.  These viruses  do not grow  in vitro.  Some amount of 
infectious  viruses  can be generated us ing a raft culture system, 
whic h forms a stratif ied squamous epithelium.  
VIRAL LIFE CYCLE 
Comprise of  attachment,  Entry,  Unc oating,  transcription of 
viral genes, Viral replication, Viral assembly and release11.  
ATTACHMENT 
 HPV binds promiscuos ly to w ide range of c ell types.  
 Heparan sulfate proteoglycans,  are important for  binding to 
some target c ells12.  
 Clathrin  mediated  endoc ytos is - allow entry of virus13.  
 HSP-70 chaperone protein has been suggested as a mediator 
of uncoating. 14 -16  
TRANSCRIPTION OF VIRAL GENES :  
 E1 & E2- Express ion occur in basal c ell,  to maintain episomal 
replic ation of HPV genome.17  
 E6 & E7 – promote proliferation of parabasal cells.  
They provide replic ation mac hinery for  viral DNA 
replic ation.  
E2 has  a repress ing effect on the viral promoter  gone.  Its  loss 
allows increased express ion of  oncogenic  proteins E6 and E7. Both 
the integration of  E6 &E7 and loss  of  E2 express ing episomes  are 
nec essary for cancer progress ion.19   
VIRUS ASSEMBLY AND RELEASE: 
HPV infec tions  are not c ytolytic,  release of  viral partic les  is 
due to desquamating c ells.  
HUMAN PAPILLOMA VIRUS AND ANOGENITAL 
WARTS: 
In 1980,  how ever Gissmann and Zer Hausen,20  isolated and 
characterized HPV 6 from a genital w art.  They define the 
etiologic al agent for  genital w arts.  Anogenital w arts  have been 
recognized as  a disease entity for  many centuries.  The term 
‘Condyloma’ is  derived from anc ient Greek meaning’ a round 
swelling adjacent to the anus’.  
 There has  been a  r is ing  tendency of  genital w art infections 
in the past few  years  (HPV 6 & 11 are respons ible for  90% of 
genital warts)   .This   ref lects  the changing cultural attitude towards 
sex and  also due to the increased awareness  among public  and the 
easy availability of health care servic es22.  
AGE GROUP: 
Anogenital w arts  most frequently occur during 2nd  and 3rd 
decades of life.23,24 As many other STD infections  HPV  also  infects 
the reproductive  age  group25.  
 INCUBATION PERIOD: 
The incubation period may vary ranging from 3 months  to 8 
months26.  The mean incubation period is  2.8 months.  upto 2/3rd  of  
sexual partners w ill develop w arts w ithin s ix months.  
 MODE  OF TRANSMISSION  OF  ANOGENITAL  WARTS :  
 Anogenital w arts  are usually acquired by sexual 
transmiss ion.27  Sexual intercourse is  the princ ipal mode of 
transmiss ion.  
 Transmiss ion from subc linic al c ases  are common.Rarely,  it 
may spread by non-sexual modes. Transmiss ion of virus from 
hand w arts is exceedingly rare.  
 Infection from the mother’s  genital tract at delivery appears 
to be the mos t common cause of  anogenital warts  in children 
presenting upto 2 years of age28 ,29.  
 Iatrogenic transmiss ion can occur in gynecology c linics 
during spec ulum examination while sharing unsterilised 
instruments  whic h can c ause spread  of   infection from one 
person to another person.  
MODES OF TRANSMISSION OF CUTANEOUS WARTS: 
The sourc e of  infection is  a c linic al or  subc linical c ase of 
HPV infection,  as well as  vir ions  whic h may be present in the 
environment.  I t is transmitted by contact directly or  indirec tly.  The 
important predispos ing factor is disruption of  the epithelium,  skin 
or muc osa.  Home,  school,  barrac ks, sw imming pools  and 
instruments  used by barbers  and c heiropodis ts and shared towels 
provide opportunities  for  spread of  the infection.30 Shaving can 
cause spread of  w arts  to different areas  of  the fac e.  Viral partic les 
have also been detected in the fumes  that emerge on treating warts 
by electrosurgery or  laser   here  the operator  is  at  the r isk of 
developing laryngeal warts.  
Certain occupations,  in whic h the individuals  are prone to 
injury and c ome in contac t w ith the f lesh of  animals  like butc hers, 
f ish and poultry workers, have high inc idenc e of w arts.  
INFECTIVITY 
Genital w arts  are the mos t infective type of w arts.  Almost 
tw o thirds of  the sexual partners  of   those  patients w ith genital 
warts   develop or  have subc linical warts.31   The HPV DNA  c an  be  
detected  w ith in a period  of   1 year  after  the infection .  The 
infectivity of  other  types  are low er.  Low  risk anogenital HPV types 
are HPV types  6 and 11 which rarely progress  to invas ive disease. 
The high r isk types  are HPV types  16 and 18 and are found in 
approximately 40 to 60% and 10 to 20% of all cervic al c arc inomas, 
respectively.  
IMMUNOPATHOLOGY 
Cell mediated immunity are essential for  the control of 
papilloma virus  infection32.  The individuals  w ith inherited immune 
defic iency affecting T c ell response are more prone to HPV 
infection.  The virus  is  not cytolytic.  It does  not  have a blood borne 
stage.33 ,34  
Humoral immunity doesnot play a s ignif ic ant role in 
preventing  HPV infection or  maintenanc e of  latency.  They may be 
a good marker of  infection and henc e a valuable epidemiologic al 
tool35.  
 
HISTOPATHOLOGY OF ANOGENITAL WARTS: 
Thickening of stratum comeum. Acanthos is and papillomatosus. 
Thickening and elongation of r ite r idges.  
‘Koiloc ytes’  are the most characteris tic  feature for  the 
diagnos is36.  The epithelial cell have the perinuc lear  halo.  The 
cytoplasm w ill be condensed peripherally. Centrally hyperchromic 
and large nuc lei w ill be seen.  
HPV TYPES: 
Bec ause of  the tissue tropism,  spec if ic   HPV types  infect 
particular  epithelium.  HPV types  1 and 2 are found to infect 
thickened skin of  palms  and soles,  caus ing palmar w arts  and plantar 
warts. The keratinized skin  and  muc osal epithelium of  anogenital  
areas   are  commonly  infected  by  types   6,11,16,18.  Types  16 and 
18 are the c ausative factors of invas ive cancers in anogenital tract.  
Clinical Features:  
Genital warts  as  a manifestation of  papilloma virus  infection 
represent the tip of  the ic eberg,  when cons idering the total spectrum 
of infection.  The Infection  may  remain  asymptomatic ,w ith out 
any disease  manifes tation37.  For many years  it may remain latent, 
unlike other  STDs it does  not produce any acute symptoms like 
discharge, itching or burning pain38.  
Clinical manifestations associated with different  
HPV types (39 ,40 ,41)  
TYPE  OF WART HPV  TYPE 
Plantar warts     1,2,4 
Common warts     2,4,1,7,57 
Plane warts     3,10,41,27 
Flat  warts  
Epidermodysplas ia 




Genital warts  
( low risk of malignanc y )  
   6,11,30,34,40,42-44 
Genital warts  
( high r isk of malignancy )  
 
   16,18,31,33,35,39,45,51 
NON –GENITAL MUCOSAL 
Mouth(focal epithelial hyperplas ia)  13,32.  
Laryngeal papilloma                         6,11 
Maxillary s inus papilloma                 57.  
Carc inoma( head,neck, lung)             16,18,30.  
Almedia theory of one way cross reactivity:  
The hand wart c an be autoinoc ulated onto the genital mucosa, 
whereas the genital warts do not produce any cutaneous les ions.  
GENITAL LESIONS 
Clinical features:  
Most HPV infections  are asymptomatic  unlike other  STD’s  it 
does not manifes t w ith symptoms like itc hing,  burning, discharge, 
majority of  the infec tions  w ith HPV does  not develop disease.  The 
tw o most common c linic al manifestations  of HPV that require 
treatment are genital w arts  and HSIL (High grade squamous  intra 
epithelial les ions).38  
Condylomata acuminata  6,11.  
Non – c ondylomatous les ions 
and or CIN 
6,11,16,18,26,27,30,31,33,34,35,39,40,42-
45,51-53,56- 9,61, 62,67-71,73,74, 81 
Carc inoma 16,18,26,31,33,35,39,45,51,53,56,58,59,66-
68,73,82.  
While a restr ic ted number of  genital HPV types  have been 
linked to the c anc er,  most have been linked to the development of  
squamous  intra epithelial les ions  of  cervix,  vagina,  vulva,  penis,  or  
anus39.  
More than 100 HPV types  are known is  occur that are 
categorised into three board c ategories  depending on their 
oncogenic potential.  
High r isk types : HPV 16,  18,  31,  32,  35,  39,  45,  51,  52,  56, 
58, 59, 68, 73, 82.  
Intermediate Types : HPV 26, 53, 66 
Low risk types : HPV 6,  11,  40,  42,  43,  44,  54,  61,  70,  72,  81 
and CPI 10840  
Within the spectrum of subc linical infection,  there are several 
distinct entities, namely 
 (1) Ac etowhite epithelium  
(2)  Macroscopically normal epithelium,  but w ith cytologic al 
or histologic al evidenc e of HPV infection, such as Koilocytes .  
(3)  Macro and microscopic ally normal epithelium in which 
HPV has  been detected by such means  as  in s itu hybridization or 
DNA amplif ic ation by PCR.41  
ROLE OF HPV IN CANCER: 
In the etiology of  anogenital c anc ers, the role of  HPV has 
been s trongly established in a large amount of  molec ular  and 
epidemiological s tudies.   After  the entry of  virus into the host c ell, 
the viral genome w ill be integrated into the host c ell.  Subsequently, 
on accumulation of further  mutations  and c o-factors,  leading to 
development of  c anc er.  E6 and E7 are the two viral genes,  that are 
invariably retained and expressed in tumours.E7 f irstly disrupts  the 
s ignal that normally prevents a cell from entering S phase once the 
cell has  left the basal layer42.  Both E6 & E7 bypasses  and damages 
the DNA c heckpoints.  They also disrupts the s ignals  inc luded in 
growth arres t.  
Inactivation of  check points leading to the genetic  instability. 
This  gives  r ise to genetic  changes  required for  tomourogenic ity. 
The exact c ombination of  the effects  of  E6 and E7 are necessary for 
immortalization and transformation.43  It is  mediated through 
whether P53 inactivation or  telomerase activation or  both is  yet to 
be s tudied44.  
PATHO-GENESIS: 
Virus s trains  -16,  E7 onc oprotein is  able to bind to the 
retinoblas toma gene product.45 Deletions or mutation of  the 
retinoblas toma gene RB1 are common features  of  many tumours 
and tumor c ell lines.  Rec ently RB1 gene product P105-RB has  been 
shown to form stable protein.  Protein complexes w ith oncoproteins 
of DNA viruses  suc h as,  adenovirus44  E1A protein and s imian virus 
40 (SV 40) large T cell antigen.  The onc oprotein E7 of  HPV-16 c an 
form s imilar  c omplexes  w ith P105-RB.46  Human papilloma virus  -
16 is detected in relation to about 50% of cervic al c arc inomas47.  
PATHOGENESIS AND PROGRESSION: 
Retinoblastoma gene has  been implic ated in many tumours.  It 
is  found that E7 onco gene protein of  HPV-16, binds  to the RB 
gene product and form complexes.  Like the oncogenic virus  Adeno 
and s imian 40 E6 Protein of HPV form stable protein complexes.  
Only certain intraepithelial les ions  progress  to invas ive 
cancers.  In CIN 1,2,3 les ions,  60%,  40% and 35% of them regress 
Spontaneous ly.  40% of CIN’s  pers is t and progress  to malignancy48 
i.e 1% of CIN, 2% of CIN2 and 5% of CIN-3 progress to Canc er.  
Co-factors in HPV Carinogenesis:  
These factors can be broadly c lass if ied as49 
 Viral co-factors  
 Host c o-factors  
 Environmental co-factors  
Viral co-factors are 
 Viral pers istence 
 HPV variants  
 Viral load and integration 
PERSISTANCE OF INFECTION 
Most of  genital HPV infections are abortive.50  Most of  the 
new  infections  c an be detectable for  less  than 2 years.  Pers is tant54 
high r isk HPV infec tions  is  a “r isk marker” for future development 
of CIN3.51 ,52  
HPV Variants 
High r isk variants inc lude HPV- 16,  18, 33,  58.  These 
variants  are assoc iated w ith CIN-3 and invas ive squamous  c ell 
carc inoma.53  
Viral Load 
High viral load assoc iated w ith r isk of CIN 2,  3.  Among 
women w ith pap abnormalities, a cons istently high viral load is  a 
predictor for progress ion to high grade les ion.54  
Host factors 
Decreased r isk of  CIN 3/ CIS and SCC are assoc iated w ith 
HLA Class  II  DRB1*13,  DRB* 1301-5 and DQB1*0603 
alleles.DRB1*13 is  assoc iated w ith increased probability of 
regress ion of CIN les ions.55  
ENVIRONMENTAL FACTORS 
Risk factors include 
 Multiple sex partners56 
 Early age of f irst intercourse 
 Multi Parity57  
 Cigarette smoking58,69  
 Hormonal contraceptive use59  
Other STD’s and HPV infection:  
By c aus ing chronic  inflammation,  Other Sexually Transmitted 
Diseases enhance the host liability to HPV.  
HSV-2 and Chlamydia trachomatis are well established co-
factors.61, 62  
Association with high parity and hormonal contraceptive use:  
1) High parity expose the transformation zone for  longer 
duration of  time making the zone susceptible to HPV 
exposure.60,61  
2) Hormonal c hanges  like increased levels  of  es trogen and 
proges terone during pregnancy c ould reduc e the immune 
response to HPV.61  
3) Oestrogen could promote viral integration into the host 
genome, and stimulate E6 and E7 oncogenes of HPV.  
HPV AND HIV 63 ,64,65 ,66  
HIV infections  has  been assoc iated w ith a greater  inc idence 
and pers istence of  CIN, HIV assoc iated w ith higher prevalence of 
cytologic  abnormalities  and histologic ally confirmed CIN. 
Detec tion of  HPV & CIN increases  as  the CD4 count falls.  Many 
studies  have show n increased r isk of  cervic al c ancer among HIV- 
pos itive w omen.  These may be mediated through HIV targeting of 
spec if ic  genes  and direct viral – viral interactions42.HIV -1 tat 
protein w ill upregulate E6 and E7 of  HPV virus,  that are 
respons ible for oncogenic potential.63  
HIV patients  infected w ith HPV present w ith large genital 
warts, at times  they bec ome loc ally invas ive and des tructive.  These 
tumours  are called giant c ondyloma’s  or  Buschke -  Lowenstein 
tumour they are non metastas izing,  carry a r isk of  transformation in 
squamous cell c arc inoma.  
PATHOGENESIS OF HIV AND HPV CO-INFECTION64  
1. HIV fac ilitates activation of recently acquired HPV infection.  
2. Causes reactivation of latent infection.  
3.  Both extrac ellular  and Intrac ellular  HIV-1 tat MRNA c an 
transac tivate HPV type 16, E6 and E7.  
4. HIV-1 tat protein also migrates  to infected epithelial c ells  to 
upregulate E6 and E7.  
HIV pos itive women are at the greates t r isk for  HPV infection 
and intraepithelial neoplas ia.  Cervic al cancer is  an AIDs  defining 
illness.  Particularly individuals  w ith CD 4+ T cell c ount less than 
200/mic rolitre are more vulnerable.  
CDC guidelines  recommends  two pap smear during initial 1st 
year after diagnos is of HIV, thereafter if normal, yearly.  
CYTOLOGY BASED CERVICAL CANCER CONTROL IN 
DEVELOPING WORLD68 ,69:  
The annual screening may decrease the cancer inc idence by 
90% or more in developing countr ies  like India.  For every one lakh 
test performed,  w e c an detect 33 c ases  of  c anc er but this  needs  45 
tests  to be performed per women67.  
This  c an be reduc ed to sc reening in every 3 years .  This  c an 
detect upto 95 c ases  of  c anc er for every 100,000 test done. It 
w ill reduc e the inc idenc e of  invas ive c ervic al c anc er by atleast 
71%6 8.  
HISTORY 
The pap smear w as  devic ed by a greek pioneer in 
cytopathology, Dr.Georgios nikolaou papanikolaou.  This  tes t is  the 
most effective screening programme.  Most effective role in cancer 
reduction programme68 ,69.  
Together  w ith Dr.Herbert Traut,  he published the book on 
diagnos is of vaginal and c ervical cancer.  
 He f irst reported that uterine cancer could be detected by 
means  of a vaginal smear in 1928.  But the s ignif icance of  his  work 
was  not accepted  until the public ation,  together  w ith Herbert Traut,  
in the  diagnos is  of  uterine c anc er by vaginal smear’  in 1943.  The 
book discusses    preparing of  vaginal and cervic al smear,  smear 
changes  during the mens trual c yc les,  the effec ts  of  various 
pathologic al c onditions  and the changes  seen in the presenc e of 
cancer of c ervix and carc inoma endometrium.  
Dr.  Georgios  Nikolaou Papanicolou work was  credited w ith 
‘‘Albert Larker Aw ard” for  his  in Clinical Medic al Research in 
195024.  
THE BETHESDA SYSTEM 
In 1989, the Bethesda sys tem was  introduced for  
standardized  reporting of  c ervic al cytology smear s tudy70.  This  c an 
be integrated w ith detec tion of  HPV to gain further  information. 
The name for  ‘‘preinvas ive squamous  les ions’’  w as c hanged to 
‘‘squamous intra epithelial les ion’’.  
The 2001 Bethesda sys tem,  recommended a protocol  for  the 
cytology report it inc ludes an report on suff ic ienc y of  spec imen, 
followed by general c ategorisation and the analys is of results.  
The general c ategorisation is  an optional component of  the 
2001 Bethesda system.  
  NIL (or) Negative for intraepithelial les ion or malignancy 
 Abnormality of the epithelial c ell 
 Others  
 INTERPRETATION/ RESULTS 
NEGATIVE FOR INTRAEPITHELIAL LESION OR 
MALIGNANCY ORGANISMS  
Include detection of organism like 
1) Tric homonas vaginalis  
2) Budding yeast forms s imilar to c andida spec ies.  
3) Bac terial vaginos is c onc luded by shif t in f lora 
4) Ac tinomyces spec ies w ith cons is tent morphology 
5) Cellular changes consistent w ith Herpes Simplex Virus (HSV). 
OTHER NON-NEOPLASTIC FINDINGS 
1) Reactive c ellular  c hanges  assoc iated w ith inflammation 
( inc ludes typic al repair)  radiation therapy,  Intra Uterine 
Contrac eptive Devic e (IUCD).  
2) Post hysterectomy status.  
3) Atrophy 
I.       Epithelial cell abnormalities  
A.Squamous cell 
1) Atypic al squamous c ell (ASC)71  
a. Atypic al squamous cells of undetermined s ignif icance (ASCUS) 
b.  Atypic al squamous  c ells  in w hich High Grade Squamous  Intra 
Epithelial Les ions cannot be exc luded HSIL (ASC-H).  
2) Human papilloma virus (HPV),  dysplas ia and c ervical intra 
epithelial neoplas ia (CIN)1 are c ategorized under Low  grade 
squamous intraepithelial les ion (LSIL) 
3) Moderate and severe dysplas ia,  Carc inoma in s itu,  CIN2 and 
CIN 3 are c ategorized under High grade squamous 
intraepithelial les ions (HSIL).  
4) Squamous c ell carc inoma.  
Glandular Cell 
1.Atypical  
a. Glandular  Cell (Not Otherw ise Spec if ied or  spec ify in 
comments)  
b. endoc ervic al Cell (Not Otherw ise Spec if ied or  spec ify in 
comments)  
c. endometrial Cell (Not Otherw ise Spec if ied or  spec ify in 
comments).  
2.Atypical  
a. glandular c ells, suggesting neoplastic  
b. endoc ervic al cells, suggesting neoplastic  
3.Endocervical adenocarcinoa in situ.  
4.Adenocarcinoma.  
II.Other 
Endometrial cells in a w omen > 40 years of age.  
THE NORMAL PAP 
Squamous Cells 
The lining epithelium of ectocervix is  stratif ied squamous 
cells.  
The ectoc ervix is lined by a stratif ied squamous  epithelium. 
This  matures  under the influence of  es trogen.  The squamous  c ells. 
w ith full maturity are called superfic ial cells.  These squamous  c ells 
have tiny pyknotic nuc lei w ith 5-6 m in diameter.  
Intermediate c ells measuring about 8 m in diameter  have a 
larger nuc lei.  The nuc leus  not pyknotic, it w ill be granular  f inely. 
Large polygonal c ells  w ith transparent pink c ytoplasm may be a 
superfic ial squamous cells or a intermediate c ell.  
During pap test,  only the upper layers are sampled. The 
immature cells  at the base are not usually sampled.  In conditions 
like low  es trogen levels,  the immature basal and parabasal c ells  w ill 
be present in upper layers also.  
Sometimes,  densely keratinised c ells  w ith small pyknotic 
nuc leus  and es inophilic  cytoplasm may be seen.  These c hanges  are 
characteris tically seen in parakeratos is. Parakeratos is  is  inc luded in 
benign reactive c hanges,  whic h is  c aused by chronic  irr itation.  With 
this  c hanges  coupled w ith nuc lear  atypia in the form of enlargement 
are membrane irregularity w ith hyperchromas ia,  they are called 
dyskeratocytes  or  atypic al parakeratos is.  This  is  c ategorized under 
epithelial c ell abnormality.  
ENDOCERVICAL CELLS 
 Endocervical cells are columnar c ells  
 They produce muc in 
 They have eccentr ic ally plac ed nuc leus  w ith a indistinct 
nuc leoli 
 This  nuc leoli become more prominent in reactive 
conditions.   
Other normal f inding are,  
 Endometrial cells whic h are exfoliated and abraded  
 Trophoblastic c ells and dec idual cells.  
INFLAMMATORY CELLS 
Inflammatory c ells  such as  neutrophils  lymphoc ytes  and 
plasma cells  may be seen in pap smear.  Presenc e of  neutrophils  in 
the c ervical spec imen donot necessarily indicate infection.  There 
are present in increased numbers af ter infection or injury.  
Very rarely,  lymphocytes  and plasma c ells  are found.  In older 
women the pattern called follic ular  c ervic itis  has  been described. 
The biopsy of  this  les ions,  shows lymphoid follicule formation. 
This  c an be c onfused w ith HSIL endometrial cells  or  lymphoma. 
His tiocytes seen in,  
- Antepartum cervix  
- Radiation therapy 
- Foreign body 
- During mens trual c yc le  
- Endometrial hyperplas ia  
- Endometrial carc inoma  
But their presenc e may be non spec if ic, w ithout s ignif ic anc e.  
 
LACTOBACILLI 
The Normal vaginal f lora is  predominantly c olonized by 
lactobac illi.  The lactobac illi are gram pos itive rod shaped bac illus. 
I t is  a c ommensal not pathogenic.  The c ellular  pattern described in 
the presence of  lac tobac illus  is  known as  c ytolys is.  Here the 
glyc ogen c ontained in the squamous  cells  are metabolized.  Hence 
the cells have not cytoplasm w ith the bare c ell nuc lei .  
ARTEFACTS AND CONTAMINANTS70  
 Cornflaking 
 Coc kle burrs  
 Tric home 
 Carpet beetle parts. 
ORGANISMS AND INFECTIONS71 ,72,73  
1 .Shift  in  flora  suggestive of bacterial  Vaginosis 
 Mixed f lora, Short, curved coccobac illi 
 Absenc e of lac tobac illi 
 Filmy appearanc e of the s lide 
 Clue c ells w ith indis tinc t margin 
Trichomonas vaginalis 
 Length is 15-30 m  
 Pear shaped 
 peripherally plac ed pink nuc lei  
 Markedly pink c ytoplasmic granules  
Candida: 
 Eosinophilic  
 Budding yeast forms whic h is 3-7 in diameter  
 Both true and pseudohyphae are seen.  
 Tangles of squamous cells around pseudohyphae .  
Actinomyces species 
 Bac terial c lumps 
 Organisms w ith elongated f ilaments  
Herpes simplex 
 Multi nuc leated giant c ell 
 Altered nuc lei  
 Peripheral loc ation of c hromatin 
 Nuc lei have a ground glass appearanc e   
 Oesinophilic intra nuc lear inc lus ion bodies  
Cytom egalovirus 
 Single nuc lear c ells  
 enlarged nuc leus  
 Intra nuc lear basophilic inc lus ion  
 Cytoplasmic inc lus ions whic h are granular  
Chlamydia trachomatis73  
 Vac uolization in the cytoplasm  
 Inflammatory infiltrate w ith predominant lymphocyte 
population.  
RARE INFECTIONS 
Amoebias is- Entamoeba histolytic a.  
Calymmato bacterium granulomatis :  
Seen as  encapsulated gram negative bacterium that is 
concentrated in macrophages  and diff ic ult to seen w ith the 
papanic olaou stain.  
REACTIVE CHANGES 
Reactive changes  may be due to the infection or  hormonal 
stimulation.  It may be due to trauma or radiation.  These reactive 
changes may mimic  squamous or  glandular  les ions,  leading to 
confus ion.   
CELLULAR CHANGES INDUCED BY RADIATION 
 Irregular giant cells.  
 Multiple nuc lear  
 The nuc lear cytoplas imc ratio w ill be normal 
 Vac uolation w ill be seen in cytoplasm    
 Cell repair features  
CELLULAR CHANGES ASSOCIATED WITH IUDS 
 Vac uolation in the c ells  
 Tiny c ells w ith resemblance to HSIL 
HORMONAL EVALUATION 
The degree of  c ell maturation varies.  Depending on the 
c irculating levels  of  estrogens,  androgens  and progestogens. 
Hormonal evaluation is performed from vagina.  
GRADING SQUAMOUS INTRAEPITHELIAL LESIONS 
The Bethesda sys tem recommends  a low  grade / high grade 
approach to grading SIL.  Most HSIL’s  are seen w ith pers istence of 
viral infec tion w hich has  the immense potential for  progress ing to 
invas ive cancer74.  
LSIL encompass   Koiloc ytes  (f lat c ondyloma) and mild 
dysplas ia (CIN 1).  This  distinction is  not reproduc ible and both 
les ions  contain a  heterogenous  distr ibution of  low risk and high 
r isk HPV types.  
HSIL encompass  les ions  previous ly described as moderate 
dysplas ia (CIN2)  and  as severe dysplas ia/ carcinoma in situ (CIN 3). 
SQUAMOUS CELL CARCINOMA75  
SCC is  the mos t common malignant tumour of c ervix 
cytomorphologic al  features  inc lude,  
 HSIL features  
- Meganuc leus  
- distr ibution of chromatin w ill be irregular  
- Morphology of  c ells  favouring malignancy ie Tumor 
diathes is  
- Tadpole c ells  
- Fiber cells  
ATYPICAL SQUAMOUS CELLS OF UNDETER MINED 
SIGNIFICANCE76 :  
 Vac uolated c ells resembling atypic al c ells  w ith mature 
cytoplasm, sugges tive of Koilocytes 
 Atrophic squamous cells  
 Parakeratos is w ith atypic ality  
 Atypic al repair  
 Atypic al c ells due to sampling and laboratory error   
Atypic ally ‘mature’  squamous c ells  w ith features suspic ious of  a 
SIL are defined as ASCUS.  
 Screening  guidel ines:                 
Different for different countries77 ,78  
1. In ideally screening should be s tarted at the the age of  20 
or 25 and c ontinuous until about the age of 50 or 60.  
2. To be continued upto the age of 50-60 years.  
3. If  the results w ere normal in routine schedule screening, 
thereafter can be repeated ever 3 years.  
4. Should not be screened before age 21. American congress of 
obstetricians and gynaecologist (ACOG) and others 
recommended s tarting screening at age 21.  
5. Screening should be s tarted atleast a few  years  (2-3 
years) after the f irst intercourse.  
6. After  an abnormal pap smears more frequent pap smears 
may be needed  
- Follow ing treatment for abnormal pap  
- Follow ing abnormal biopsy results  
- Follow ing after treatment for c anc er.  
7. A doc tor  may suggest having the test more often if  a 
women has  certain r isk factors  such as  human 
immunodefic iency virus  infection or  a c ompromised or 
defective immune system.  
8. Women aged 70 years  or  more w ho have had no 
abnormal results  in the previous  10 yrs  may stop c ervic al 
screening78.  
9. Women aged 70 years  or  more w ith three  or  more 
consec utive normal pap results c an stop cancer 
screening.  
10. After  the removal of c ervix while under going total 
hysterectomy the screening is  not done.  But n c ase if  the 
hysterectomy w as  done for  c ervical cancer or 
prec anc erous  intraepithelial les ions  screening should be 
as usual79.  
Effect iveness and limi tations o f pap  smear: 
Pap test has  both the negative predic tive value and pos itive 
predictive valve.  The result can be both false negative or  false 
pos itive.  
The mean sens itivity of the pap tes t is  47% (range 30-80%) 
and the mean spec if ic ity is 95% (range 86-100%).  
Adenocarc inoma of endocervix which constitute about 15% 
of all cervic al cancers  has  not been prevented by PAP test. 
Moreover this has a low tes t sens itivity for detecting CIN 2 and 
CIN 3 leisons, w ith the sens itivity range from 47% to 62% 80  
To increase the sensitivity of PAP test 
1. Repeat PAP can be done 
2. Liquid based cytology (LBC) can be used  
3. High r isk HPV types detection c an be done 
4. Detec tion of  HPV in self collected spec imen from 
vaginal wall or urine81  
5. Combined w ith visualisation of c ervix.   
6. Non HPV related molecular  markers  that c an be used 
are PCNA, P16 INK 4a,  Ki 67 (MIB-1),  cdc 6 and 
mcm5, Telomerase, c yc lin E.  
The false negative rate for  invas ive cervic al c anc er ranges 
from 16% to 82%. This may be due to  
1. Sampling error  
2. Laboratory error  
To identify 33 cases  of c anc er one women has  to undergo 43 
test, for every 100,000 tests.  
The annual screening w ith pap smear c an reduce the cancer 
inc idence to 93%.  An organised screening programme w ith the 
regular  follow  up c an reduc e the cancer rate by 80%-90% the 
failure of this reduction may b due to follow ing reasons.  
 Sampling error  
 Interpretation error  
 Not getting regular follow up of abnormal results  
 Not getting screening regularly.  
PREVENTION: 
Consis tent use of  condom w ith regular partners  has  not been 
shown to  affect the outcomes  or  manifestations  of  HPV infection. 
Like most other STD’s  the best method of prevention is ABC.  
 Abstinence82  
 Be faithful to the partner  
 Condom usage.  
The HPV Vaccines:  
The pers istence of  HPV infection   due to failure to c lear 
HPV from infected c ells  is  due to defective host immune response 
or a defec tive viral immune evas ion mechanism.  
To improve hos t immune response to c lear  invading HPV,two 
‘L1  virus  like partic le’  HPV vacc ines  are available, a quadrivalent 
vacc ine (Gardas il)  involving HPV- type 6,  11,  16,  18 and bivalent 
vacc ine (Cervarix)  involving the two most prevalent HPV 
oncotypes 16 and 18.  
They are adminis trated as  three intramuscular  injections  in 
3doses,  1st  dose on day 1,  2nd dose 1 month later,  and 3rd dose 6 
months later.  
Can be given from the age of  9 yrs.Ideally before the onset of 
sexual ac tivity.  
These vacc ines  are c onferr ing protection against the two most 
common high r isk HPV assoc iated w ith c ervic al c anc ers in young 
women.  They should be uninfected by these two types  at the time of 
vacc ination83.  
The HPV vacc ines  appear to provide protection from HPV 
infection up to 3 years in studies84.  
MANAGEMENT OF ABNORMAL CYTOLOGY RESULTS: 
MANAGEMENT OF WOMEN WITH ASCUS85 :  
Repeat PAP screening (or)  c ombine PAP c ytology w ith 
adjunctive method like HR-HPV DNA testing.  It found pos itive, 
immediate colposcopy to be done.  
 MANAGEMENT OF WOMEN WITH ASC-H:  
Directly referred for  colposcopic  evaluation.  If  found 
negative repeat cytology at 6 and 12 months.  
MANAGEMENT OF WOMEN WITH LSIL: 
The women should be referred for colposcopic evaluation.  
MANAGEMENT OF WOMEN WITH HSIL: 
Women w ith PAP smear c ytology c ons itent w ith high grade 
squamous  intra epithelial les ions should be referred to undergo 
colposcopic evaluation. Endoc ervic al assessment should be done.  
For confirmed HSIL,  the w omen should undergo immediate 
LEEP for c ytologic al abnormalities.Only if invas ion is suspected,  a 
diagnostic exc is ional proc edure is recommended.  
 
 
AIMS AND OBJECTIVES  
A Study on prevalenc e of  abnormal cervic al c ytology us ing 
PAP smear as  a screening proc edure among the attendees  of  female 
STD OPD.  
• To study epithelial c ell abnormality.  
• To study the assoc iated STIs.  
• To detect benign c ellular changes.  
• To reinforc e the practice to do PAP smear routinely.  
 
MATERIALS AND METHODS 
STUDY DESIGN 
Cross-sectional study.  
STUDY GROUP 
 500 female patients  w ere enrolled in the s tudy female .All 
the female patients attending the STD OP Department.  
 The ethic al committee c learance w as  obtained and informed 
consent w as taken from the recruited w omen.  
INCLUSION CRITERIA: 
• All the women aged 19 and above after  vaginal sexual 
exposure.  
EXCLUSION CRITERIA: 
• Pregnant Women & lactating women.  
• Females during their  mens trual cyc le 
• Women below 19 years  
• Females before vaginal intercourse 
• Women who had a total hysterectomy for  c auses  other  than 
cervic al c anc er 
After  the fulf illment of  inc lus ion criter ia w ere inc luded in 
this s tudy.  
A detailed history w as  obtained pertaining to the follow ing 
parameters  -  age,  occupation,  soc ioec onomic  s tatus,  educ ational 
status,  marital his tory,  sexual,  contraceptive,  obstetr ic,  past, 
personal,  recent treatment history,  history sugges tive of systemic 
ailments,  and sexually transmitted infections  related symptoms as 
per the proforma enc losed.  
EXAMINATION PROCEDURES DONE IN OP SECTION: 
The c linic al examination cons isted of  local inspec tion of 
external genitalia for  any growth,  swelling or  ulc er.  This  is 
followed by visualization of  the vagina and cervix w ith a non 
lubricated speculum.  
EXAMINATION 
A thorough genital examination w as  done us ing Cusco’s  self 
retaining bivalve speculum and the abnormalities  in the vulva, 
vagina and c ervix were noted.  The amount, odour, c olour and 
cons istency of  vaginal discharge were noted.  The discharge w as 
labeled sc anty if  it w as  insuffic ient to collec t on the speculum; 
moderate if  it w as  suff ic ient to collec t on the speculum and profuse 
if  it w as  vis ible at the introitus  even before speculum insertion.  The 
vaginal pH w as  measured directly us ing pH indicator  str ips against 
the lateral vaginal wall or over speculum blade.  
Firstly,  spec imens  for  cervic al c ytology w ere obtained from 
ec toc ervix w ith a wooden spatula rotated 360o  and from endoc ervix 
w ith a cytobrush. Slides were f ixed immediately w ith spray 
f ixative.  
Vaginal sw abs  w ere obtained for  vaginal pH,  w hiff  test,  and 
wet mount mic rosocopy.  
Next the ec toc ervix w as  w iped c lean w ith large cotton swabs. 
Endocervical spec imens  were obtained us ing cotton swab for  gram 
stain and gonococcal c ulture.  
Screening for  HIV antibody us ing an ELISA technique w as 
performed.  
Serologic al screening for syphilis was  routinely performed.  
Papanicolau s taining was  done in the venerology lab,  institute 
of venereology, Madras Medical College, Chennai-3.  
Staining was done w ith rapid pap staining kit.  
Side lab procedures in STD 
Dark field microscope 
Only method of  demonstrating T.Pallidum.  Identif ied by 
movements.  
Gram Staining 
A thin smear is  prepared from the spec imen c ollected over a 
c lean ster ile glass  s lide.  The smear may be f ixed w ith the Bunsen 
burner f lame86 ,87.  
1) The smear is  f looded w ith 1% methyl violet for  1 minute. 
Washed w ith distill w ater.  
2) Then again f looded w ith the mordant gram’s  iodine for  1 
minute and then washed w ith dis til water.  
3) Then discolourised w ith acetone for 2 seconds.  
4) After  washing  w ith dis till w ater,  counter  stain w ith dilute 
carbol fuschin for 30 seconds.  
5) To be visualized under oil immers ion,  the gram negative STD 
pathogens like gonococci and calymmatobacterium 
granulomatis c an be seen.  
From the posterior  blade of  the c usco’s  self  retaining 
speculum,  the spec imen for  the wet mount w ith normal saline and 
potass ium hydroxide are collected.  
KOH mount 
A  thin  smear prepared over the c lean glass  s lide is  covered 
w ith 10% KOH to be left for  5minutes  and them viewed under 
mic roscope, fungal elements  can be seen as  budding yeast w ith the 
pseudohyphae.  
Wet mount:  
After  preparation of  the thin smear over the c lean glass  s lide, 
1% normal saline is used to mount the smear and visualized w ithin 
seconds  for  the tr ic homonas  vaginalis  organism.  Diagnos is  of 
Tric homonas  vaginalis  infection w as done by this method. 
T.vaginalis  is  identif ied as pear-shaped organisms  about the s ize of 
a pus  c ell w ith typic al jerky /erratic  tw itching movement.  The 
spec imen should remain moist to retain viability and therefore the 
motility of the Trichomonads ( the microscopy should be performed 
w ithin 30 min of preparation of the w et mount)86.  
 A minimum of 104  organisms per  milliliter  of  vaginal f luid 
appears  to be necessary for  the identif ic ation of  the Tric homonas 
vaginalis by wet mount.  
Pap smear  
Papanicoloau s tained smears have demonstrated T.vaginalis 
on c ytologic al examination in asymptomatic  w omen.  How ever, 
detection us ing the Papanicolaou tes t results  in a high perc entage of 
false-negative results  w ith a sens itivity of  60% and a spec if ic ity of 
95–97%.(87 ) Confirmation us ing another method is rec ommended.  
Trichomonas Vaginalis Culture:  
Culture in liquid medium has  remained the gold standard for 
the diagnos is  of  Trichomonas  vaginalis  infection for the pas t 40 
years  and has  the higher sens itivity of  71-100% and spec if ic ity of 
100%.[27 ] Various  media that have been used to detect 
Tric homonads are Diamond (Triptic ase, yeas t and maltose), 
Modified Diamond,  Kupferberg’s  Tric hosel medium, Lash, NIH, 
Feinberg-Whittington media and c ysteine peptone liver  media 
(CPLM).  
The use of  in Pouch TV c ulture system has  been shown to be 
at least as effective as Diamond’s medium.[73 , 82]  
MICROBIOLOGICAL PROCEDURES: 
Vaginal candidias is  and Trichomonias is  were diagnosed by 
wet mount microscopy.  The diagnos is  of  bacterial vaginos is  are 
arr ived at by use of  Amsel’s  cr iter ia.  Cervic itis  was  diagnosed 
c linic ally by presenc e of  mucopurulent  endocervic al discharge 
and/or  additional s igns  of  c ervic al inflammation suc h as  eas ily 
induced endoc ervic al bleeding and oedema.  An active case of 
syphilis  was  diagnosed by either  a pos itive dark f ield examination 
or  a new ly reactive VDRL or  a 4 fold r ise in non treponemal 
antibody titre (VDRL)in  patients w ith previous  history of  
syphilis 88.  
Genital herpes  s implex (HSV) and genital warts w ere 
diagnosed c linic ally.  
CERVICAL CYTOLOGY: 
Smear were performed at female STD op at Ins titute of 
venerology, Madras Medic al College, Chennai.  
FOLLOW UP OF PATIENTS WITH ABNORMAL RESULTS: 
Patients  w ere informed that they would be contacted by  
phone c all in the event of  an abnormal results, and were asked to 
provide a reliable phone number and mailing address.  Patients  w ith 
unsatis factory smears  w ere invited for  c linic  for  a repeat smear. 
Patients  w ith atypical smears  were asked to undergo repeat  pap 
after 3 months.  
Patients w ith SIL were advised for gynecology follow up.  
DIAGNOSIS  
1.Trichomonias is : Diagnos is  was  made based on the 
follow ing: 
Wet mount:  
A drop of  normal saline w as  put over a c lean ,  grease free  
mic roscopic  s lide.  To this  a drop of  vaginal f luid was  added and 
mixed w ell.  A cover s lip was  put over the mixture,  so that there w as 
a uniform spread w ithout air  bubble.  The s lide was  observed under 
40 x magnific ation of the objective88.  
Reading: Pear  shaped f lagellated organisms  approximately 
the s ize of  lymphocyte (10-20 µm) or  that of  a small neutrophil 
w ith characteristic jerky movements.  
Culture:  
Diagnos is is made by performing wet mounts from the drop 
of  Diamond’s  culture media for  evidence of  motile Trichomonads 
by examining cultures  after  48 hours  of  incubation and on 3rd,  5th 
and 7th day.  
2. Bacteria l  vaginosis: Diagnos is  was  made based on Amsel’s 
cr iter ia in which presence of  three out of  the four cr iter ia is 
nec essary:  
a. Exc ess ive homogenous  uniformly adherent vaginal 
discharge.  
b. Vaginal pH more than 4.5.  
c. Pos itive amine test (Whiff tes t).  
d. Presenc e of c lue cells on mic roscopic examination.  
3. Candidiasis: Diagnos is  w as  made based on pos itive 
mic roscopy and/or culture.  
4. Mucopurulent  cerviciti s: Those patients  whose Gram’s  stain of 
cervic al smear having 30 or  more polymorphonuc lear 
leukocytes per oil immers ion f ield in cervic al mucus.  
5. Pelvic inflammatory disease (PID): A diagnos is  of  PID w as 
made if in addition to the presenting symptoms of  abnormal 
vaginal discharge and lower abdominal pain,  c ervical motion 
tenderness was elic ited on examination.  
 
RESULTS 
The study w as conducted in Institute of Venereology, Madras 
Medic al College,  Chennai.  500 female patients  attending the 
outpatient department were enrolled in the study.  
Total number of patients in the study group- 500.  
TABLE-1.1: PREVALENCE OF ABNORMAL, NORMAL & 
INFLAMMATORY PAP SMEAR 
 Fre quency Percent 
Normal 148 29.6 
Abnormal 46 9.2 
Inflammatory smear (IS) 306 61.2 
Total 500 100.00 
Among the total 500 pap smears,  normal s tudy w as  found in 
148 pap smears  (29.6%),  Abnormal pap smear results  in 46 smears 
(9.2%). Inflammatory smear is 306 (61.2%) among 500 smears.  
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Fig-1: Prevalence of Abnormal, Normal & Inflammatory Pap 
Smear 
TABLE-1.2: PREVALENCE OF INFLAMMATORY SMEARS 
HAVING MONOCYTES AND LYMPHOCYTE POPULATION, 
 Fre quency Percent 
Normal 160 32.0 
Abnormal 34 6.8 
Inflammatory smear (IS) 211 42.2 
Inflammatory Smear (Monocytes)  38 7.6 
Inflammatory Smear (Neutrophils)  57 11.4 
Total 500 100.0 
 Among the 306 inflammatory smears,  38(7.6%) smears  have 
predominant monocytes  and lymphocyte population,  57(11.8) 
smears have neutrophils predominantly .  
TABLE-1.3: VARIOUS GRADES OF ABNORMAL PAP 
SMEAR 
 Fre quency Percent 
Not Applicable 454 90.8 
HSIL 3 0.6 
CA 4 0.8 
AT 33 6.6 
LSIL 6 1.2 
Total 500 100 
Among the total number of  abnormal pap smear s tudy results. 
Atypic al squamous c ells is found in majority that is (6.6%), next is 
the CA (0.8%),  high grade and low grade squamous intra epithelial 
les ions  c ontr ibute  0.6% and 1.2% eac h to the abnormal pap smear 
study results. This table is exc luding inflammatory pap smear.  





Not Applicable HSIL CA AT LSIL
 
Fig 2: Shows the distribution of LSIL, Atypical squamous cells, 
HSIL and carcinoma among study population  
HSIL - High grade Squamous Intraepithelial Les ion 
CA - Carc inoma 
AT - Atypic al Squamous Cell 
LSIL - Low grade Squamous Intraepithelial Les ion 
2. SOCIO-DEMOGRAPHIC FEATURES 
TABLE-2.1: PREVALENCE OF ABNORMAL PAP SMEAR 
STUDY AMONG DIFFERENT AGE GROUPS 
Age  Normal Abnormal Inflammatory smear Total 
30 2 59 91 
18 to 25 
31.9% 2.2% 64.8% 100% 
56 22 100 178 
26 t0 35 
31.5% 12.4% 56.2% 100% 
45 10 105 160 
36 t0 45 
28.1% 6.3% 65.6% 100% 
17 12 42 71 
>45 
23.9% 16.9% 59.2% 100% 
148 46 306 500 
Total 
29.36% 9.2% 61.2% 100% 
Majority of  abnormal pap smear s tudy was  found in the age 
group of  >45  ie 16.9 %.Bimodal  age distr ibution  seen  between 
the age  groups 26-35 and  age group >45.  
 Majority of  inflammatory smear s tudy w as  found in the age 
group of  36-45,  it constitute 106 smear(34.6%) out of  306 total 
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PREVALENCE OF ABNORMAL PAP SMEAR STUDY AMONG 
DIFFERENT AGE GROUPS
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Fig 3:Shows Age distribution of the study group s pap smear 
f inding 
TABLE-2.2: ABNORMAL PAP SMEAR AMONG RURAL AND 
URBAN POPULATIONS 
Address  Normal Abnormal Inflammatory Total 
62 19 124 205 
Rural 
30.2% 9.3% 60.5% 100% 
86 27 182 295 
Urban 
29.2% 9.2% 61.7% 100% 
148 46 306 500 
Total 
29.6% 9.2% 61.2% 100% 
 Inflammatory pap smear results  among rural and urban found 
to be ins ignif icant.  Abnormality in urban population (9.2%)  and  
rural (9.2%) population  remains the  same.  
 
 
TABLE-2.3: PREVALENCE OF ABNORMAL PAP SMEAR 
RESULTS AMONG PATIENTS HAVING DIFFERENT 
OCCUPATION 
Occupation Normal Abnormal Inflammatory smear Total 
62 12 113 187 
Coolie 33.2% 6.4% 60.4% 100 
% 
9 10 32 51 
CSW 
17.6% 19.6% 62.7% 100% 
52 18 143 213 
House w ife 
24.4% 8.5% 67.1% 100% 
25 6 18 49 
Others  
51% 12.2% 36.7% 100% 
Total 148 46 306 500 
Majority of  patients  w ith abnormal cervic al c ytology 
belonged to commerc ial sex w orkers  (CSW) group (19.6%) next 
high prevalenc e belong to housew ives  group (8.5%).This 
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Fig 4: Shows the different occupation of the study groups and pap 
sm ear finding in them 
TABLE-2.4: DISTRIBUTIONOF ABNORMAL PAP SMEAR 
AMONG LOW INCOME, MIDDLE AND HIGH INCOME 
GROUP 
Monthly Income  Normal Abnormal Inflammatory smear Total 
90 20 143 253 
Low Income 
35.6% 7.9% 56.5% 100% 
44 20 112 176 
Upper Lower 
25% 11.4% 63.6% 100% 
8 4 31 43 
Low er Middle 
18.6% 9.3% 72.1% 100% 
6 2 20 28 
Upper middle 
21% 7.1% 71.9% 100% 
0 0 0 0 Upper 
 0 0 0 0 
Among the abnormal pap smear results  majority of  them belonged 
to low inc ome (7.9%)and upper low er (11.4%).  Middle income 



























DISTRIBUTION OF ABNORMAL PAP SMEAR AMONG 
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TABLE-2.5: COMPARISON OF EDUCATIONAL STATUS 







75 29 139 244 I lliterate & 
Primary school 
education 
31.1% 11.8% 57% 100% 
68 13 130 211 
Secondary 
32.2% 6.2% 61.6% 100% 
5 4 37 46 
Graduate 
10.9% 8.7% 80.4% 100 
148 46 306 500 
Total 
29.6% 9.2% 61.2% 100% 
Abnormal pap smears  seen in majority among illiterate 
(11.8%) .  Next majority of  patients  have completed their   secondary 
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COMPARISON OF EDUCATIONAL STATUS WITH 
RESULTS OF ABNORMAL PAP SMEARS
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Fig 6: Education Status of the study population 
 
TABLE-2.6: METHOD OF CONTRACEPTION 
Me thod of 
Contra 
Normal Abnormal Inflammatory Total 
5 2 10 17 
OCP 
29.4% 11.8% 58.8% 100% 
6 0 14 20 
Copper T 
30% 0 70% 100% 
2 0 0 2 
Barrier Method 
100% 0 0 100% 
87 24 175 286 Permanent 
Sterilization  30.4% 8.4% 61.2% 100% 
48 20 107 175 No 
Contrac eption  27.4% 11.4% 61.1% 100% 
148 46 306 500 
Total 
29.6% 9.2%  61.2% 100% 
In this s tudy only 2 patients  used the barr ier  contraception 
regularly.  Majority of patients in this  study has  undergone 






























































Fig 7: Method of contraception in study population 
3. STATUS OF THE PARTNER 
TABLE-3.1: SPOUSE ASSESSMENT 
Spouse Assessment and 
Follow up 
Normal Abnormal Inflammatory Total 
1 0 2 3 
Genital Ulc er  
33.3% 0 66.7% 100% 
1 2 5 8 Genital/Urethral 
Discharge 12.5% 25.20% 62.5% 100% 
127 31 247 405 
Not Done 
33.9% 9.6% 59.6% 100% 
2 1 8 11 
Syphilis  
27.3% 0 72.7% 100% 
1 1 9 11 
HIV 
9.1% 9.1% 81.8% 100% 
1 1 1 3 
Balanoposthitis  
33.3% 33.3% 33.3% 100% 
13 11 41 65 
Not applicable  
20% 16.9% 63% 100% 
148 46 306 500 
 Total 
29.6% 9.2%  61.2% 100% 
Among the 50 patients  in w hom spouse assessment w as  done. 
Spouse of  3 patients  presented w ith balanoposthitis.  Among 3 
patients one had abnormal cervic al cytology (33.3%).  
Among the 8 spouse who presented w ith uretheral or  genital 






































































Fig 8: Diagnosis of spouse  
 
 
TABLE-3.2: SHOWS HUSBAND WITH EXTRAMARITAL 
CONTACT 
 Normal Abnormal Inflammatory Total 
119 4 261 384 
Absent 
30.9% 1% 68% 100% 
4 6 5 15 
Present 
26.6% 40% 33.3% 100% 
10 9 21 40 
Unknown 
25% 22% 52.5% 100% 
14 27 20 61 Not 
Applic able 22.9% 44.2% 32.7% 100% 
148 46 306 500 
Total 
29.6% 9.2%  61.2% 100% 
In husband of  patients  having extramarital contact out of  the 
15 assessed,  6 were found to have abnormal c ervical c ytology.  The 
abnormality is  1% in the patient w ho’s  husband have no 
extramarital contac t 
4. SEXUAL HISTORY 
TABLE-4.1: SHOWS MARITAL STATUS OF THE STUDY 
POPULATION 
Marital status  Normal Abnormal Inflammatory Total 
135 35 265 435 
Group 1 
31% 8% 60.9% 100% 
13 11 41 65 
Group 2 
18% 16.9% 63.1% 100% 
148 46 306 500 
Total 
29.6% 9.2%  61.2% 100% 
Group 1: Living w ith the spouse 
Group 2: Patient inc luding CSW, Widowed, Divorced 
separated.  
Not living w ith the spouse inc ludes,  commerc ial sex workers, 
Widow,  divorced and separated group of  patients.  The group 2 
patients  had the increased abnormal c ervic al c ytology (16.9%) 
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Fig 9: Shows Marital Status of the study population 
TABLE-4.2: ASSOCIATION OF PAP SMEAR 
ABNORMALITY WITH THE NO. OF PARTNERS 
No. of 
Partners  
Normal Abnormal Inflammatory Total 
136 29 254 419 
Single 
32.5% 6.9% 60.9% 100% 
12 17 52 81 
Multiple 
14.8% 21.0% 64.2% 100% 
148 46 306 500 
Total 
29.6% 9.2% 61.2% 100% 
Abnormality of  pap smear found to be assoc iated more w ith 
the patients  having multiple partners  (21%) than patients  having 
s ingle partners (6.9%).  
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Fig 10: Shows the pap smear f indings among patients having 
multiple partners & single partners 
 
TABLE-4.3: ASSOCIATION WITH SEXUAL HISTORY 
Se xual history Normal Abnormal Inflammatory Total 
4 9 28 41 
Pre-marital c ontact 
8.3%       22% 68% 100% 
11 9 20 40 
Extra marital contact 
27.5% 22.5% 50% 100% 
1 0 1 2 
Previous venereal disease 
50.0% 0 50.0% 100% 
132 28 257 417 
Nil 
32.2% 6.8% 61.0% 100% 
148 46 306 500 
Total 
29.6% 9.2%  61.2% 100% 
Majority of  abnormal pap smear results  correlated w ith the 
patients  having history of  extramarital c ontact (22.5%).  next w ith 
the patients having history of premarital c ontact (22%) Patients 
w ith history of  previous  venereal disease have 50% inflammatory 
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Fig 11: Pap smear finding among study population having history 
of Pre-Marital contact, Extra-Marital and Previous Venereal 
disease 
5. EXAMINATION FINDINGS 
TABLE-5.1: PREVALENCE OF CERVICAL EROSION 
AMONG ABNORMAL PAP SMEAR 
Per spe culum 
Examination Normal Abnormal 
Inflammatory 
smear  Total  
26 4 49 79 
Discharge 
32.9% 5.1% 62.0% 100% 
30 24 97 151 
Eros ion 
19.9% 15.9% 64.2% 100% 
2 0 2 4 
Growth 
50%         0 50% 100% 
   90   18 158 266 
Nil 
34.9% 5.6% 64% 100% 
148 46 306 500 
Total 
29.6% 9.2%  61.2% 100% 
On speculum examination of the attendees  of  STD c linic, 
Eros ion w as  found to be s ignif ic antly assoc iated w ith abnormal pap 
smear (15.9%).  Cervic al or  vaginal discharge is  found  in 5.1% of 
the abnormal pap smear.   This  assoc iation were found to be 
statistic ally s ignif ic ant (P<0.05).   
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TABLE-6.1: PREVALENCE OF ABNORMAL PAP SMEAR 
AMONG VAGINAL DISCHARGE  
Diagnosis  Normal Abnormal Inflammatory Total
42 33 144 219 
STD 
19.1% 15% 65.7% 100%
36 11 82 129 
Others  
27.9% 8.5% 63.5% 100%
70 2 80 152 
Non Venereal  
46% 1.3% 52.6% 100%
Total 148 46 306 500 
Abnormal pap smear most commonly assoc iated w ith 
sexually transmitted disease (15%).  Non venereal disease are only 
1.3% assoc iated.  This  assoc iation is  found to be s ignif icant in 
Chisquare tes ts.  
Next to the STD,  other  causes  like c ervic itis and Lower 



























TABLE-6.2: PREVALANCE OF ABNORMAL PAP SMEAR 
AMONG VAGINAL DISCHARGE 
Diagnosis  Normal Abnormal Inflammatory Total
5 17 63 85 
Bac terial vaginos is  
5.6% 20% 75.1% 100%
6 3 15 24 
Candidias is  
25% 12.5% 62.5% 100%
7 0 16 23 
Tric homonas Vaginalis  
30.4% 0% 69.5% 100%
15 10 29 54 
Other Vaginal Discharge 
28% 18.5% 53.7% 100%
9 3 21 33 
Other STD’s  
27.2% 9% 63.6% 100%
36 11 82 129 Other (Cervic itis  and 
Low er abdominal Pain)  27.9% 8.5% 63.5% 100%
70 2 80 152 
Non Venereal  
46.1% 13.1% 52.6% 100%
Total 148 46 306 500 
The most c ommon STD seen among abnormal Pap smear is 
bacterial vaginos is  (20.0%) next is  the vaginal discharge syndrome 
(18.5%).  Other c linical diagnos is  mos t commonly assoc iated w ith 
abnormal pap smear in the order  of  frequenc y are candidias is 








































TABLE-6.3: PREVALANCE OF ABNORMAL PAP SMEAR 
AMONG OTHER STD’s  
Diagnosis  Normal Abnormal Inflammatory Total
3 2 9 14 
HSV 
21.4% 14.2% 64.2% 100%
1 1 11 13 
HIV 
7.6% 7.6% 84.6% 100%
4 0 0 4 
Syphilis  
100% 0 0 100%
1 0 1 2 
Anogenital Warts  
50% 0 50% 100%
36 11 82 129 Other (Cervic itis and Low er 
abdominal Pain)  27.9% 8.5% 63.5% 100%
70 2 80 152 
Non Venereal  
46% 1.3% 52.6% 100%
33 30 123 186 
Vaginal discharge syndrome 
17.7% 16.1% 66.1% 100%
Total 148 46 306 500 
Other than vaginal discharge syndromes  and Other STD’s 
assoc iated w ith abnormal pap smear in the order of  frequency are 































Normal Abnormal Inflammatory  
Fig 15: prevalence of various STDs 
TABLE- 6.4: SHOWS  PREVALENCE  OF  ABNORMAL  
FINDING  AMONG  VARIOUS  PRESENTING  
COMPLAINTS.  
Presenting Complaints  Normal Abnormal Inflammatory Total 
81 7 135 216 Asymptomatic  
37.5% 3.2% 62.5%% 100% 
33 30 123 186 Vaginal Discharge 
17.7% 16.1% 66% 100% 
6 2 8 16 I tching Genitalia 
37.5% 12.5% 50% 100% 
1 0 1 2 Warty Growth 
50% 0 50% 100% 
4 0 0 4 Syphilis  
100% 0 0 100% 
1 0 0 1 Dysparunia 
100% 0 0 100% 
7 1 4 12 Pain Abdomen 
58.3% 8.3% 33.3% 100% 
14 0 0 14 Others  
100% 0 0 100% 
3 2 9 14 
Genital ulc eration 21.4% 14.2% 64.2% 100% 
0 0 8 8 Infertility  
0 0 o100 100 
2 4 5 11 Contact Trac ing 
18.2% 36.4% 45.5% 100% 
1 0 1 2 Bartholin’s Cyst 
50% 0 50% 100% 
0 0 1 1 Low Bac k ache 
0 0 100% 100% 
1 1 11 13 HIV tes t 
7.6% 7.6% 84.6% 100% 
148 46 306 500 Total 
29.6% 9.2%  61.2% 100% 
REASON FOR ATTENDING THE STD OPD 
Among  the 46 patients of  abnormal c ytology in this   s tudy 2 
(4%) patients  presented w ith genital ulc eration.  4 (8%) patients 
attended for  contact trac ing,  30 (62.5%) patients, presented w ith 
vaginal discharge,  7 (15.2%) patients  are asymptomatic,  2 patients 
(4%) presented w ith itching genitalia.  
DISCUSSION 
During the s tudy period,  500 patients  were enrolled for  pap 
smear study.  
The perc entage of  normal pap smear study among the 
attendees  was  29.6%.  The prevalence of  the abnormal c ervic al 
cytology among the attendees  of  female STD op w ere found to be 
9.2% (95% C.I). The inflammatory smear cons titutes  about 62.1% 
In STD c linics,  various  studies  have reported a prevalenc e rates  of 
squamous  intra epithelial les ions  or  dysplas ia ranging from 5% to 
11%.  This prevalence is  reasonably more than the other  family 
c linics.  
This study was comparable with the study done by Feldman et al90 
in w hich 7% had abnormal cervic al cytology.  This  was  also 
comparable w ith the study done by Kanno MB et al93  in which 5.7% 
of the satisfactory spec imens  were abnormal.  This  was  also 
comparable w ith the s tudy done by RM Briggs  et al92  in which 
11.4% of prevalence of  screening abnormalities  c ons is tent w ith 
CIN.  This  study was  comparable w ith the study of  Feldman et al90 
and Edel man et al91.  This  s tudy w as  also comparable to study done 
by Shlay JC et al94  in which a typical c ells  (12.6%) prevalence is 
w ithin the range of the s tudy.  
Among the 46 abnormal pap results  3 (6%) womens  had High 
grade squamous  intra epitheial les ion.  4(8.6%) w omens  had 
f indings favouring malignancy.  6(13%) womens  had low grade 
squamous  intra epithelial les ions.  33 w omen had atypic al squamous 
cells of undetermined s ignif icance.  
This  s tudy w as  cons istent w ith Edelman et al91  in whic h 9.9% 
had cytology cons istent w ith ASCUS, of whic h 2.5% is LSIL.  
The prevalence perc entage may vary depending on the group 
studies.  In this  s tudy in addition to the high r isk group,  normal 
population has also been inc luded as they are referred for HIV 
screening from other departments for surgical procedures.  
Among the abnormal pap smear results. 6.6% belong to atypical 
cells, 8.6% belong to carc inoma, 6% of High grade squamous intra 
epithelial les ion.  Low  grade squamous  intra epithelial les ion seen in 
6(13%) patients.  
This  results  are comparable to the s tudy done by Law ley TB, 
Lee RB,  Kapela R et al95  in which atypic al cells  are 7.8%,  HSIL is 
4.1% and LSIL is 15.5%.  
Inflammatory smear is seen in 306 patients  out of  500 
patients. This  constitutes 62.1%.  This is  cons istent w ith the study 
done by Law ley TB et al95  in which the reactive changes  were noted 
in 67.5%.  This  s tudy is  also comparable to the study done by Gupta 
Ashami et al96 in which inflammatory cytology is noted in 53%.  
Among the inflammatory smear (306) monocytes  were found 
in 7.6%, and neutrophils  were found in 11.8% of cases. This  may 
represent Ac ute on the c hronic infections.  
SOCIO DEMOGRAPHIC FEATURES:  
Age: Table 2.1 
The prevalenc e of  abnormal pap smear study were found to be 
greater  in w omen 26-35 years  of  age (11.4%) than in the women 
greater  than 35 years  of age.  Another peak was  found in age group 
>45(16.9%).This  represents bimodal age distr ibution of  abnormal 
cervic al cytology.  As  all the STI,  are found to be greater in the 
reproductive age group.  This s tudy also shows the prevalence of 
abnormal pap smear higher among the reproductive age group.  This 
is comparable to the study done by Schewbke JR et al97 in which 
study they also found pap smear abnormality more in the age group of  
20-39 year (23%). Also cons istent with study done by Manjit et al106 
in which mean age of LSIL is 32.3 years and mean age of HSIL 40 years.  
In this s tudy,  abnormal pap smear prevalence were found to 
be greater  among urban population (8.0%) than rural population 
(4.4%).  
This  study was  done in Institute of  Venerology,  Madras 
Medic al College,  Chennai.  This  assoc iation may not be s ignif ic ant 
as most of our study population belong to urban areas.  
Occupation: Table 2.3 
The pap smear abnormality were found to be greater  among 
CSW (17.6%) than other  groups.  Next,  Housew ives  form the major 
group in this  study (8.9%). The prevalenc e of inflammatory 
cervic al c ytology among this  group w ere found to be 67.1%.  Next 
major group belong to Coolie 60.3%.  This  is  c omparable to the 
study done by RM Briggs  in w hich CIN increase w ith the r ise in the 
number of partners.  
Out of  the 51 c ommerc ial sex workers  inc luded in this  study 
10 (19.6%) of  them had abnormal pap smear.  32 (19.6%) of them 
had inflammatory smears.  9(17.6%) of  them had normal s tudy in 
pap smear.  This is c ons is tent w ith s tudy done by Gitsh G et al98.  in 
whic h increase prevalence among prostitutes were found.  
 
Socio Economic Status: Table 2.4 
Abnormal pap smear cytology were found to be assoc iated w ith 
lower and middle soc io-economic group (9.3%) than high income 
group (7.1%). This is in concordance w ith Feidman MJ et al91 s tudy 
in whic h it is 7%.  
Educational Status: Table 2.5  
11.8% of the illiterate women and those who w ere in primary 
education level inc luded in this  s tudy had abnormal c ervic al 
cytology.  This  observation w as c oncordanc e w ith the study 
conducted by Lyttle H99 in whic h there w as increased rate of 
abnormal pap smear study among lower educational s tatus.  
Method of contraception: Table 2.6  
Abnormal c ervical c ytology was  present in 11.8% of patient 
us ing oral contrac eptives  pills  (11.8%) next higher prevalenc e seen 
in patients w ho doesnot used any c ontrac eption  
Number of Partners: Table 3.1 
The abnormal pap smear cytology was  found to direc tly 
related to the number of partners.  Among the 46 abnormal pap 
smear 17 (36%) patients  had multiple partners.  Of them 36% had 
Abnormal pap smear results.  In women having multiple partners  the 
abnormal c ytology w ere found in 67.8%.  This is  in concordance 
w ith the pilot study done by Lyttle H et al99  in whic h they found 
that the abnormal cytology rate increases  w ith increas ing no of 
sexual partners.  In this  study 40 (8%) of  patients  had extra marital 
contact.  Out of  40,  9 patients  had abnormal c ervic al c ytology.  In 
this  study we found that the inflammatory cytology were more 
common w ith the increas ing years of married life.  
History of pre marital and Extra marital contact: Table 3.2 
In this study, the abnormal cervical cytology is present in 18/46 
(39.1%) patients who have the H/o of premarital or extra marital 
contacts. This was comparable with the study done by Gupta Ashima et 
al96 in which 24% had history of extramarital contact.  
Martial Status: Table 3.3 
Abnormality of  pap smear cytology were found to be greater 
among women not living w ith the spouse (82.0%).  This  may be 
attr ibuted to the increased number of  sexual partners  among the  
women not living w ith the spouse rather  than women  living w ith 
the spouse.  
Spouse Assessment: Table 4 
In this  s tudy,  spouse assessment has  been done for  50 c ases, 
out of  w hich 3 patients  presented w ith balanopos thitis,  14 patients 
w ith the HIV anti body pos itivity. 4 patients w ith VDRL reac tivity.  
In this  s tudy w e found that the pap smear abnormality is  more 
in the women who have more than 3 c hildren (17%) and in women 
who had married at an early age.  In this  study we found increased 
number of  abnormality w ith increas ing years  of  married life.  14.3% 
of patients married s inc e 10-15 years had abnormal c ytology.  
In this s tudy maximum number of  patients  have undergone 
permanent ster ilization.  
Examination 
On speculum examination,  among the 46 abnormal smears, 
4(8.6%) patients  presented w ith c ervic al disc harge.  64.2% 
presented w ith cervic al eros ion.  Cervic al eros ion is  the most 
cons istent f inding assoc iated w ith abnormal c ervic al cytology.  
Diagnosis:  
In this   study we found that  16(34.7%) cases   out of  46  c ases 
having  abnormal cervic al cytology  has  been found to be 
assoc iated w ith  sexually transmitted diseases .  
In this  study,  the most common condition   assoc iated w ith 
abnormal c ervic al cytology was  bacterial vaginos is  17/46 (36.9%) 
next was  the other  vaginal discharge (negative for  TV,  candida and 
BV)  was  found in 10(28.2%)patients.  Others  are cervic ities  and 
lower abdominal pain 11/46 (23.9%).  
Out  of   80 patients   diagnosed as   non venereal conditions 
only 2 (4.3%) had abnormal c ervical cytology .This   differenc e w as 
statistic ally s ignif ic ant w ith p valve < 0.05.  
This  is  cons istent w ith study done by shlay et al94  and law ley 
et al95  in whic h vaginal discharge is  found in 60% of patients.  The 
prevalenc e of  STD among CIN is  71.7%.  The prevalenc e of  STD 
among benign f indings are 40%.  
This  is  cons istent w ith the s tudy done by c ampbell et al100  in 
whic h the prevalence of  STD among CIN is  78% and among benign 
is 46%.  
SUMMARY 
In this study the follow ing observation has been made.  
1) In this s tudy the prevalenc e of   abnormal  c ervical c ytology 
was  found to be 9.2% .  Among  the 48 abnormal c ytology 
smears,   4 patients  had carc inoma (8.6%),3 patients   had 
HSIL (6.5%),6 patients  had LSIL(13.0%)   and  33 
patients(6.6%)   had atypic al c ells   on cytology among 500 
patients.   
2) Among  the 46 c ases  of  abnormal   c ytology  22(47.8%) 
patients belonged to  the age group  of  26 -35 and 12(26%) 
patients belonged to the age group of  >45 .  Bimodal age 
distr ibution of  abnormal c ervic al c ytology has been noted  
3) 43.4% of women who had abnormal cytology res ide in urban 
area.  
4) 18 (39%)patients  out of   46 patients  found  to have  abnormal 
cervic al c ytology  w ere housew ives.12 (26%)  patients   w ere 
coolie.  
5) 86% of the  46 women w ith the abnormal c ervic al c ytology 
belonged to low and middle income group.  
6) Among  46 patients   ,29 (63%) women  w ere in the primary 
education level .  
7) Women having   more than 3 children had increased 
prevalenc e (17%) of  abnormal c ervical cytology ,as  compared 
w ith the w omen  having 2  children (9%).  
8) Women w ith multiple partners  had increase prevalenc e of 
abnormal c ytology (21%) c ompared to the w omen w ho had 
s ingle partner(9%)   
9) Out of  17 patients,  who had been on OCP pills  for 
contraception 11.7% had abnormal pap smear  incontrast ,   2 
patients   who practic ed  barr ier  contraception both(100%) had 
normal cervic al c ytology reading.  In this  study maximum 
number of patients under gone permanent ster ilization.  
10) Prevalence  of   abnormal c ervic al  c ytology is  more among 
women w ith  increas ing years  of  married life   .out of 46 
women   21 (45.6%) had been married s ince more than 15 
years   and 13 (28.2%) of  them had  been married  s ince  10 -
15 years.  
11) On spouse assessment genital  ulcer (4.3%) and 
balanopos thitis  (2.1%) w ere found to be assoc iated w ith 
abnormal cytology of their partners.  
12) Among  15 women whos  spouse  had extra marital c ontact 6  
(40%) of  them had abnormal cervic al c ytology in contrast in 
women w ith the spouse w ith no extra marital contact  only 
1% had abnormal c ervical c ytology .  This  is  found to be 
statistic ally s ignif ic ant .  
13) Abnormal  c ervic al cytology was  found to be  greater  among 
women who are not living w ith the spouse 16.9% c ompared to 
the women  living w ith the  spouse 8%.  Women not living 
w ith the spouse inc lude  commerc ial sex workers,w idowed 
,separted and divorc ed.This  increased prevalenc e in this 
group may be attr ibuted to multiple partners in them.  
14) In  this  study  9 w omen w ere referred  through  their  male 
partner  to our STD OPD  ,among them 4 (44.1% )had pos itive  
f indings for abnormal cervical cytology 
CONCLUSION 
 In this  study w e found 9.2% of prevalence of  abnormal 
cervic al c ytology and inflammatory pap smear were found in 
61.2%.  Hence the yield of  screening in STD c linics  w ill be 
higher  in STI c linics, than in other c linics.  
 The r isk factors found to be assoc iated w ith abnormal 
cervic al c ytology inc ludes  reproductive age group,  lower 
soc io-economic  and lower educational s tatus,  multiparity, 
multiple partners,  assoc iated other  sexually transmitted 
diseases.  
 Early screening and detection of  dysplas ia w ill reduce the 
morbidity and mortality assoc iated w ith carc inoma c ervix.  
 Inflammatory pap smear were found to be 62.1%.  This 
inflammatory pap smear warrants, repeated pap smear after 
treating the infection followed by repeat pap smear in 3 
months,  and 6 months.  Pers istant inflammatory c ytology 
warrants further investigations and follow up.  
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Pap Smear Kit (Cyto Brush, Ayre’s Spatula)  
 
PATIENT CONSENT FORM 
 
Title of the study:-“ A Study on prevalence of abnormal cervical cytology using  PAP smear 
as a screening procedure among the attendees of female STD OPD”. 
 
Nam e of the Participant: 
______________________________________________________. 
Nam e of the Principal (C o-Investigator):  
Nam e of the Institution: Rajiv Gandhi Government General Hospital, C hennai. 
Documentation of the informed consent 
I _____________________________ have read the information in this form (or it has been 
read  to me). I was free to ask any questions and they have been answered. I am over 18 years 
of age  and, exercising my free power of choice, hereby give my consent to be included as a 
participant  in the study.. 
1 I have read and understood this consent form and the information provided to me. 
2 I have had the consent document explained to me. 
3 I have been explained about the nature of the study. 
4 My rights and responsibilities have been explained to me by the investigator. 
5 I agree to cooperate with the investigator and I will inform him/her immediately if I 
suffer unusual symptoms. 
6 I have not participated in any research study within the past _________month(s). 
7 I am aware of the fact that I can opt out of the study at any time without having to 
give any 
8 reason and this will not affect my future treatment in this hospital. 
9 I hereby give permission to the investigators to release the information obtained from 
me as result of participation in this study to the sponsors, regulatory authorities, Govt. 
agencies, and IEC. I understand that they are publicly presented. 
10 My identity will be kept confidential if my data are publicly presented 
11 I am aware that if I have any question during this study, I should contact at one of the 
addresses listed above. By signing this consent form I attest that the information given 
in this document and the HIV consent form has been clearly explained to me and 
apparently understood by me, I will be given a copy of this consent document. 
                                                                                                     Participant’s Initials: 
__________ 
For adult participants: 
Name and signature / thumb impression of the participant  
(or legal representative if participant incompetent) 
_______________                 _________________                   _______________ 
Name                                      Signature                                     Date 
Name and Signature of impartial witness (required for illiterate patients): 
_______________                _________________                    _______________ 
Name                                     Signature                                      Date 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining consent: 
_______________               _________________                   _______________ 













Information to Participants 
(This is only a guideline – Relevant changes to be made as per the study requirements) 
Sponsor (if any) : NO 
Investigator      
(principal and at least one C o-investigator)  
 
        
Nam e of Participant : - 
Title: “A Study on prevalence of abnormal cervical cytology using  PAP smear as a 
screening procedure among the attendees of female STD OPD” 
You are invited to take part in this study. The information in this document is meant 
to help you decide whether or not to take part. Please feel free to ask if you have any queries 
or concerns. 
You are being asked to participate in this study being conducted in Department of 
STD, Institute of Venereology, Madras Medical College, Chennai-3. 
What is the Purpose of the Research (explain briefly):  
The annual world wide burden of Cervical Cancer is over 530000 new cases and 
275000 deaths with majority occuring in low and middle income groups. A major issue is co-
infection with HIV which further increases the risk for cervical cancer. In  STD clinic, 
women are at the increased risk of cervical cancer as a result  of HPV infection and other 
associated STIs. Cervical Cytology using PAP smear is an effective low cost screening test 
for preventing invasive cervical cancer. The aim of my study is to know the prevalence of 
abnormal Cervical cytology using PAP smear as a screening procedure among the attendees 
of female STD OPD. 
 The Study Design 
 This study was designed to study the prevalence of abnormal PAP smear cytology 
among women attending STD clinic, who are at the risk for cervical cancer as a result of 
HPV infection, cervical disease or history of cervical disease compared with the women with 
out this characteristics. 
Study procedures: 
A Study on prevalence of abnormal cervical cytology using  PAP smear as a screening 
procedure among the attendees of female STD OPD  
Women of Childbearing Potential 
You must not participate if your are pregnant, breast feeding a child . 
Possible risks to you: Nil 
possible benefits to you:  Early treatment and avoidance of complications 
Possible benefits to other people: 
The result of the research may provide benefits to the society in terms of advancement of 
medical knowledge. (The sponsor of the research________________________________ will 
also benefit from the results of study, if positive.) 
Confidentiality of inform ation obtained from  you 
You have right to confidentiality regarding the privacy of your medical information (personal 
details ,results of physical examinations, and your medical history). By signing this 
document, you will be allowing the research team investigators , other study personnel, 
sponsors IEC and any person or agency required by law like Drug Controller General of India 
to view your data , if required. 
This information from this study ,if published in scientific or presented at scientific meetings 
will not reveal your identity. 
How will your decision to not participate in study affect you? 
Your decisions to not participate in this research study will not  affect your medical care or 
your relationship with investigator or institution. Your doctor will still take care of you and 
you will not lose any benefits to which you are entitled. 
Can you decide to stop participate in study in once you started? 
The participation in this is purely voluntary and have the right to withdraw from this study at 
any time during course of the study without giving any reasons. 
























































































































































































































































































































































1 4 2 3 1 1 1 MO 4 2 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
2 3 2 3 1 1 1 MU 4 2 2 4.00 4.00 N N P 1.00 N NEG P NEG NEG NEG P NR NEG 4 2
3 4 2 1 1 1 1 MO 4 2 4 1.00 1.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
4 3 2 1 1 1 1 MO 3 5 4 2.00 2.00 S E P 3.00 N NEG P NEG NEG NEG N NR NEG 4 7
5 5 1 1 1 1 1 MO 4 2 4 2.00 2.00 N E P 2.00 N NEG P NEG NEG NEG N NR NEG 4 5
6 2 1 1 1 1 1 MO 1 1 4 2.00 2.00 N N 2 3.00 N NEG NEG NEG NEG NEG P NR NEG 4 2
7 5 2 1 1 1 1 MU 4 7 2 3.00 3.00 U N N 3.00 N NEG NEG MNG NEG NEG N NR NEG 4 8
8 1 2 1 1 1 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
9 2 2 1 1 1 1 MO 3 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
10 3 2 3 1 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 9
11 1 2 1 1 2 1 MO 1 1 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
12 3 1 1 2 3 1 MO 4 1 4 3.00 3.00 N D P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
13 3 2 1 1 2 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
14 2 1 3 1 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
15 2 1 3 1 3 1 MO 4 2 4 3.00 3.00 N E P 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
16 2 1 1 1 4 1 MO 3 2 4 2.00 2.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
17 2 2 3 1 3 1 MO 1 2 4 1.00 1.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
18 2 1 3 2 2 1 MO 4 1 4 3.00 3.00 N E N 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
19 2 1 3 3 3 1 MO 3 2 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
20 2 1 3 2 2 1 MU 1 2 1 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
21 1 2 3 3 3 1 MO 2 9 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 2 9
22 3 2 3 3 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
23 3 1 1 1 1 1 MO 4 1 4 4.00 4.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
24 1 2 1 2 3 1 MO 1 2 4 0.00 0.00 N E N 1.00 N NEG NEG NEG NEG NEG N 1:16 R NEG 4 SY2
25 3 2 3 3 3 1 MU 4 2 1 4.00 4.00 N E N 3.00 N C C NEG NEG NEG N NR NEG 4 5
26 1 2 2 3 4 2 MU 1 7 1 4.00 7.00 U N Y 3.00 Y P P MNG NEG NEG N NR NEG 5 8
27 3 2 3 2 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9






















































































































































































































































































































































29 3 1 3 3 2 1 MO 2 8 4 0.00 0.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
30 3 1 3 2 3 1 MU 4 2 1 5.00 5.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
31 2 1 3 2 2 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
32 4 1 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
33 2 1 3 2 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
34 1 1 3 2 3 1 MO 2 2 4 3.00 3.00 N E P 1.00 N P NEG NEG NEG NEG N NR NEG 4 6
35 3 2 2 2 3 1 MO 4 7 4 3.00 3.00 U N P 3.00 N NEG NEG NEG NEG NEG N NR POS 4 8
36 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
37 3 1 3 2 4 5 MO 4 1 4 3.00 3.00 N E P 3.00 Y NEG Y NEG NEG NEG N NR POS 7 12
38 4 2 3 2 3 1 MO 4 1 4 4.00 4.00 N N P 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
39 2 2 3 2 1 1 MO 3 1 4 1.00 1.00 N E P 3.00 N C P NEG NEG NEG N NR NEG 4 5
40 1 1 3 2 3 1 MO 2 2 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
41 3 2 3 2 4 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
42 3 2 3 3 4 1 MO 4 11 4 3.00 3.00 G N P 3.00 Y NEG P NEG NEG NEG N NR POS 4 12
43 3 1 1 2 3 1 MO 4 2 4 2.00 2.00 N E N 3.00 N NEG P NEG NEG NEG N NR NEG 4 6
44 2 2 1 2 2 1 MO 1 4 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
45 3 1 3 1 3 1 MO 4 11 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
46 3 2 1 1 1 1 MO 4 1 4 0.00 0.00 N D N 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
47 2 2 3 1 2 1 MO 3 11 4 2.00 2.00 N N N 3.00 N NEG P NEG NEG NEG N NR NEG 4 5
48 2 2 5 1 2 1 MO 3 1 4 1.00 1.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
49 2 1 3 3 3 1 MO 4 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
50 1 2 2 3 3 1 MO 1 2 1 7.00 N D C 3.00 N C P NEG NEG NEG N NR NEG 4 5
51 3 2 2 2 2 1 MO 4 1 4 4.00 4.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
52 5 1 3 1 3 1 MO 4 2 4 4.00 4.00 N G P 2.00 N NEG P NEG NEG NEG N NR NEG 4 2
53 1 2 1 1 3 1 MO 1 8 4 0.00 0.00 N N N 3.00 N NEG P NEG NEG NEG N NR NEG 4 5
54 1 2 3 2 3 1 MO 1 2 4 0.00 0.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
55 3 2 3 2 4 5 MO 4 11 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3






















































































































































































































































































































































57 2 1 1 2 4 1 MO 3 5 4 2.00 2.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
58 2 2 3 2 3 1 MO 3 9 4 2.00 2.00 N N P 2.00 Y NEG NEG NEG NEG NEG N Reactive Idil ® NEG 4 4
59 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
60 2 2 5 2 3 1 MO 4 5 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
61 1 1 5 2 3 1 MO 2 5 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
62 1 2 3 3 3 1 MO 1 2 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
63 2 1 3 1 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
64 4 2 3 2 4 1 MO 4 11 4 1.00 1.00 N N N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
65 4 2 3 2 4 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
66 2 1 1 1 1 1 MO 3 1 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
67 1 2 4 3 4 1 MO 1 5 4 0.00 0.00 S N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
68 2 1 3 2 4 1 MO 4 2 4 2.00 2.00 N E P 3.00 N C C NEG NEG NEG N NR NEG 4 5
69 1 1 1 1 1 1 MO 2 3 4 1.00 1.00 N E C 3.00 N NEG C NEG NEG NEG N NR NEG 4 6
70 3 2 3 2 4 5 MO 4 2 4 2.00 2.00 N D N 2.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
71 2 2 2 3 3 5 MU 1 2 4 3.00 3.00 N E N 3.00 N NEG P NEG NEG NEG N NR NEG 4 6
72 1 2 2 3 3 2 MU 1 1 1 0.00 0.00 N N N 3.00 N C NEG NEG NEG NEG N NR NEG 5 5
73 1 2 2 3 3 2 MU 1 1 4 6.00 N N N 3.00 N NEG NEG NEG NEG NEG N R, TPHA + NEG 5 10
74 1 2 2 3 4 2 MU 1 2 1 0.00 0.00 N N P 3.00 N TV P NEG NEG NEG P NR NEG 2 TV
75 1 1 2 2 4 1 MU 1 2 1 2.00 2.00 N N N 3.00 N C C NEG NEG NEG N NR, TPHA+ NEG 6 5
76 1 1 3 2 3 1 MU 2 1 2 0.00 0.00 N N P 3.00 N P P NEG NEG NEG N NR, TPHA + NEG 6 10
77 2 2 2 2 3 1 MU 4 1 2 2.00 2.00 N E P 2.00 N P P NEG NEG NEG N NR NEG 4 6
78 1 2 2 2 3 1 MU 2 1 2 1.00 1.00 N N N 3.00 Y C C NEG NEG NEG N NR NEG 5 5
79 2 2 1 2 3 1 MO 4 11 4 3.00 3.00 N N 2 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
80 2 1 2 3 2 1 MU 2 1 2 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 7 5
81 2 2 2 2 3 1 MU 3 12 1 0.00 0.00 G E P 3.00 N NEG P NEG NEG NEG N NR NEG 7 12
82 2 2 3 2 3 1 MO 1 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
83 1 1 3 1 1 1 MO 2 1 4 2.00 2.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5






















































































































































































































































































































































85 3 2 3 1 1 1 MO 3 1 4 2.00 2.00 N D N 3.00 N C NEG NEG NEG NEG N NR NEG 4 5
86 3 2 3 1 3 1 MO 4 1 4 3.00 3.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
87 3 1 3 1 1 1 MO 4 1 4 1.00 1.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
88 2 1 3 1 3 1 MO 2 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
89 3 1 3 1 1 1 MO 4 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
90 2 2 3 1 3 3 MO 3 1 2 6.00 N D N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
91 3 1 3 1 2 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
92 3 2 5 1 3 5 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
93 3 2 5 1 1 1 MO 3 2 4 3.00 3.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
94 3 2 3 1 3 1 MO 4 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
95 3 2 5 1 1 1 MO 4 2 4 2.00 2.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
96 2 2 1 1 1 1 MO 2 1 4 2.00 2.00 N D N 2.00 N NEG Sec NEG NEG NEG N NR NEG 4 3
97 2 2 1 1 2 1 MO 2 1 4 3.00 3.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
98 2 2 1 1 2 1 MO 2 1 4 2.00 2.00 N D N 1.00 N NEG Sec NEG NEG NEG N NR NEG 4 6
99 5 1 5 1 1 1 MO 4 1 4 5.00 5.00 N N N 2.00 N NEG NEG NEG NEG NEG N R, TPHA +V NEG 4 10
100 3 1 1 1 3 1 MO 3 1 4 3.00 3.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
101 3 2 1 1 1 1 MO 3 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
102 2 2 1 1 2 1 MO 2 1 4 2.00 2.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
103 4 1 1 1 1 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
104 4 1 1 1 1 1 MO 4 2 4 1.00 1.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
105 4 2 1 1 1 1 MO 4 1 4 3.00 3.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
106 3 2 1 1 2 1 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
107 1 2 1 1 3 1 MO 1 1 4 1.00 1.00 N E N 3.00 N NEG NEG NEG MNG NEG N NR NEG 4 6
108 2 2 1 1 2 4 MU 2 3 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 1 6
109 3 1 1 1 3 1 MO 4 2 4 4.00 4.00 N E N 3.00 N P P NEG NEG NEG N NR NEG 4 6
110 3 1 1 1 1 1 MO 4 1 4 3.00 3.00 N D N 1.00 N tv P NEG NEG NEG P NR NEG 4 2
111 5 2 1 1 1 1 MO 1 1 4 5.00 5.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6






















































































































































































































































































































































113 3 2 3 1 1 1 MU 4 2 2 4.00 4.00 N N P 1.00 N NEG P NEG NEG NEG N NR NEG 4 2
114 4 2 1 1 1 1 MO 4 2 4 1.00 1.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
115 3 2 1 1 1 1 MO 3 5 4 2.00 2.00 S E P 3.00 N NEG P NEG NEG NEG N NR NEG 4 7
116 5 1 1 1 1 1 MO 4 2 4 2.00 2.00 N E P 2.00 N NEG P NEG NEG NEG N NR NEG 4 5
117 2 1 1 1 1 1 MO 1 1 4 2.00 2.00 N N 2 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 2
118 5 2 1 1 1 1 MU 4 7 2 3.00 3.00 U N N 3.00 N NEG NEG MNG NEG NEG N NR NEG 4 8
119 1 2 1 1 1 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
120 2 2 1 1 1 1 MO 3 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
121 3 2 3 1 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 9
122 1 2 1 1 2 1 MO 1 1 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
123 3 1 1 2 3 1 MO 4 1 4 3.00 3.00 N D P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
124 3 2 1 1 2 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
125 2 1 3 1 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
126 2 1 3 1 3 1 MO 4 2 4 3.00 3.00 N E P 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
127 2 1 1 1 4 1 MO 3 2 4 2.00 2.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
128 2 2 3 1 3 1 MO 1 2 4 1.00 1.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
129 2 1 3 2 2 1 MO 4 1 4 3.00 3.00 N E N 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
130 2 1 3 3 3 1 MO 3 2 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
131 2 1 3 2 2 1 MU 1 2 1 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
132 1 2 3 3 3 1 MO 2 9 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 2 9
133 3 2 3 3 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
134 3 1 1 1 1 1 MO 4 1 4 4.00 4.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
135 1 2 1 2 3 1 MO 1 2 4 0.00 0.00 N E N 1.00 N NEG NEG NEG NEG NEG N 1:16 R NEG 4 SY2
136 3 2 3 3 3 1 MU 4 2 1 4.00 4.00 N E N 3.00 N C C NEG NEG NEG N NR NEG 4 5
137 1 2 2 3 4 2 MU 1 7 1 7.00 U N Y 3.00 Y P P MNG NEG NEG N NR NEG 5 8
138 3 2 3 2 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
139 2 2 3 1 3 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9






















































































































































































































































































































































141 3 1 3 2 3 1 MU 4 2 1 5.00 5.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
142 2 1 3 2 2 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
143 4 1 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
144 2 1 3 2 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
145 1 1 3 2 3 1 MO 2 2 4 3.00 3.00 N E P 1.00 N P NEG NEG NEG NEG N NR NEG 4 6
146 3 2 2 2 3 1 MO 4 7 4 3.00 3.00 U N P 1.00 N NEG NEG NEG NEG NEG N NR POS 4 8
147 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
148 3 1 3 2 4 5 MO 4 1 4 3.00 3.00 N E P 3.00 Y NEG Y NEG NEG NEG N NR POS 7 12
149 4 2 3 2 3 1 MO 4 1 4 4.00 4.00 N N P 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
150 2 2 3 2 1 1 MO 3 1 4 1.00 1.00 N E P 3.00 N C P NEG NEG NEG N NR NEG 4 5
151 1 1 3 2 3 1 MO 2 2 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
152 1 1 3 1 1 1 MO 2 1 4 2.00 2.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
153 3 1 3 1 1 1 MO 4 1 4 3.00 3.00 N D N 1.00 N tv NEG NEG NEG NEG P NR NEG 4 2
154 3 2 3 1 1 1 MO 3 1 4 2.00 2.00 N D N 3.00 N C NEG NEG NEG NEG N NR NEG 4 5
155 3 2 3 1 3 1 MO 4 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
156 3 1 3 1 1 1 MO 4 1 4 1.00 1.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
157 2 1 3 1 3 1 MO 2 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
158 3 1 3 1 1 1 MO 4 1 4 2.00 2.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
159 2 2 3 1 3 3 MO 3 1 2 6.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
160 3 1 3 1 2 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
161 3 2 5 1 3 5 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
162 3 2 5 1 1 1 MO 3 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
163 3 2 3 1 3 1 MO 4 1 4 2.00 2.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
164 3 2 5 1 1 1 MO 4 2 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
165 2 2 1 1 1 1 MO 2 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
166 2 2 1 1 2 1 MO 2 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
167 2 2 1 1 2 1 MO 2 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3






















































































































































































































































































































































169 3 1 1 1 3 1 MO 3 1 4 3.00 3.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
170 3 2 1 1 1 1 MO 3 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
171 2 2 1 1 2 1 MO 2 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
172 4 1 1 1 1 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
173 4 1 1 1 1 1 MO 4 2 4 1.00 1.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
174 4 2 1 1 1 1 MO 4 1 4 3.00 3.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
175 3 2 1 1 2 1 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
176 1 2 1 1 3 1 MO 1 1 4 1.00 1.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
177 2 2 1 1 2 4 MU 2 3 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 1 3
178 3 1 1 1 3 1 MO 4 2 4 4.00 4.00 N E N 3.00 N P P NEG NEG NEG N NR NEG 4 6
179 3 1 1 1 1 1 MO 4 1 4 3.00 3.00 N D N 1.00 N tv P NEG NEG NEG P NR NEG 4 2
180 5 2 1 1 1 1 MO 1 1 4 5.00 5.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
181 3 2 1 1 1 1 MO 4 13 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 3 10
182 3 2 1 1 1 1 MO 3 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
183 2 2 1 1 1 1 MO 3 8 4 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
184 2 2 1 2 1 1 MO 1 1 4 2.00 2.00 N E N 3.00 Y NEG NEG NEG NEG NEG N NR NEG 4 5
185 2 1 1 1 3 1 MO 1 2 4 1.00 1.00 N N N 1.00 N C C NEG NEG NEG N NR NEG 4 5
186 3 1 1 1 1 1 MO 4 1 4 4.00 4.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
187 3 1 5 2 3 1 MO 3 1 4 3.00 3.00 N E N 3.00 Y NEG NEG NEG NEG NEG N NR NEG 4 4
188 5 2 1 1 1 1 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
189 4 2 1 1 1 1 MO 4 1 4 5.00 5.00 N D P 3.00 N C P NEG NEG NEG N NR NEG 4 6
190 3 1 1 1 1 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
191 5 2 1 1 1 1 MO 4 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR POS 7 12
192 2 2 1 1 1 1 MO 3 2 4 2.00 2.00 N N P 2.00 P NEG P NEG NEG NEG N NR NEG 4 3
193 1 2 5 2 2 1 MO 2 1 4 2.00 2.00 N N P 2.00 Y Y Y NEG NEG NEG N NR NEG 4 4
194 3 2 5 2 1 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
195 3 2 1 1 3 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9






















































































































































































































































































































































197 3 1 5 1 3 1 MO 4 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
198 5 2 1 1 2 1 MO 4 1 4 1.00 1.00 N N P 1.00 N NEG P NEG NEG NEG N NR NEG 4 9
199 5 2 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
200 4 2 5 1 2 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
201 2 2 1 2 3 1 MO 3 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
202 2 2 1 1 3 1 MO 3 2 4 2.00 2.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 7
203 3 2 2 2 3 1 MU 4 2 1 4.00 4.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
204 1 2 5 3 3 1 MO 1 1 4 0.00 0.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
205 4 1 1 1 1 1 MO 4 4 2 4.00 4.00 N E P 3.00 Y NEG NEG NEG NEG NEG N NR NEG 4 4
206 1 2 1 1 4 1 MO 1 2 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
207 4 2 5 2 3 1 MO 4 2 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
208 2 1 3 2 3 1 MO 2 1 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
209 2 1 1 1 1 1 MO 1 2 4 1.00 1.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
210 1 2 1 1 3 1 MO 2 2 4 0.00 0.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
211 2 2 1 1 3 1 MO 1 1 1 0.00 0.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
212 2 2 1 1 1 1 MO 3 1 4 2.00 2.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
213 4 2 3 1 1 1 MO 4 11 4 4.00 4.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
214 3 2 1 1 3 1 MO 4 4 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 13
215 4 2 1 1 1 1 MO 4 1 4 2.00 2.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
216 1 2 5 3 3 1 MO 1 5 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 7
217 3 2 1 1 1 1 MO 4 1 4 4.00 4.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
218 2 1 5 3 3 1 MO 2 2 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
219 2 1 1 2 3 1 MO 3 2 1 2.00 2.00 N N N 1.00 N TV NEG NEG NEG NEG N NR NEG 4 2
220 2 1 1 1 1 1 MO 3 2 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
221 2 1 5 1 2 1 MO 2 2 4 3.00 3.00 N D P 3.00 P NEG P NEG NEG NEG N NR NEG 4 6
222 2 2 5 1 3 1 MO 3 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
223 2 2 1 1 3 1 MO 4 1 4 2.00 2.00 N N P 3.00 P NEG P NEG NEG NEG N NR NEG 4 3






















































































































































































































































































































































225 3 2 1 1 3 1 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
226 2 2 1 1 3 1 MO 4 2 4 2.00 2.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 5
227 3 1 1 1 1 1 MO 4 11 3 0.00 0.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
228 4 1 1 1 1 1 MU 4 1 1 4.00 4.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 13
229 3 1 2 1 2 1 MO 3 2 4 2.00 2.00 N E P 3.00 N NEG P NEG NEG NEG N NR NEG 4 6
230 3 1 1 1 1 1 MO 2 4 4 4.00 4.00 N D N 3.00 N NEG P NEG NEG NEG N NR NEG 4 5
231 2 2 2 1 2 1 MU 1 4 1 1.00 1.00 N E P 2.00 N NEG P NEG NEG NEG N NR NEG 4 5
232 3 1 3 2 2 2 MO 2 2 2 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
233 2 1 2 2 1 1 MO 3 4 4 2.00 2.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
234 2 2 1 2 1 2 MU 1 2 4 2.00 2.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
235 3 1 1 1 1 1 MO 2 1 1 3.00 3.00 N N P 2.00 N C C NEG NEG NEG N NR NEG 4 5
236 2 2 1 1 2 1 MU 1 2 1 2.00 2.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
237 3 1 1 2 1 2 MO 2 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
238 2 1 1 2 2 3 MO 2 1 2 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
239 1 2 2 1 1 2 MU 2 2 1 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
240 2 1 1 1 1 1 MO 1 1 2 0.00 0.00 N N N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
241 3 1 2 2 2 1 MU 3 2 1 2.00 2.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
242 2 2 2 3 3 1 MU 3 2 1 3.00 3.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
243 3 1 5 3 1 1 MO 4 1 4 1.00 1.00 N E N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
244 3 1 1 2 2 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
245 2 2 3 1 3 3 MO 2 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
246 2 2 3 2 1 2 MO 3 9 4 2.00 2.00 N N N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
247 2 2 1 1 2 1 MO 2 2 2 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 4
248 3 2 2 2 3 1 MU 3 1 4 3.00 3.00 N E P 3.00 N NEG NEG NEG NEG MNG N NR NEG 4 8
249 3 2 2 3 4 3 MU 3 1 4 2.00 2.00 N E P 1.00 N TV NEG NEG NEG NEG P NR NEG 4 2
250 2 1 1 1 2 1 MU 2 2 2 3.00 3.00 N E P 3.00 N NEG NEG NEG NEG MNG N NR NEG 4 8
251 1 1 3 2 2 1 MO 1 1 4 2.00 2.00 N N N 1.00 N TV NEG NEG NEG NEG P NR NEG 4 2






















































































































































































































































































































































253 3 2 3 1 1 1 MU 4 2 2 4.00 4.00 N N P 1.00 N NEG P NEG NEG NEG N NR NEG 4 3
254 4 2 1 1 1 1 MO 4 2 4 1.00 1.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
255 3 2 1 1 1 1 MO 3 5 4 2.00 2.00 S E P 3.00 N NEG P NEG NEG NEG N NR NEG 4 7
256 5 1 1 1 1 1 MO 4 2 4 2.00 2.00 N E P 2.00 N NEG P NEG NEG NEG N NR NEG 4 3
257 2 1 1 1 1 1 MO 1 1 4 2.00 2.00 N N 2 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 2
258 5 2 1 1 1 1 MU 4 7 2 3.00 3.00 U N N 3.00 N NEG NEG MNG NEG NEG N NR NEG 4 8
259 1 2 1 1 1 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
260 2 2 1 1 1 1 MO 3 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
261 3 2 3 1 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 9
262 1 2 1 1 2 1 MO 1 1 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
263 3 1 1 2 3 1 MO 4 1 4 3.00 3.00 N D P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
264 3 2 1 1 2 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
265 2 1 3 1 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
266 2 1 3 1 3 1 MO 4 2 4 3.00 3.00 N E P 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
267 2 1 1 1 4 1 MO 3 2 4 2.00 2.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
268 2 2 3 1 3 1 MO 1 2 4 1.00 1.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
269 2 1 3 2 2 1 MO 4 1 4 3.00 3.00 N E N 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
270 2 1 3 3 3 1 MO 3 2 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
271 2 1 3 2 2 1 MU 1 2 1 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
272 1 2 3 3 3 1 MO 2 9 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 2 9
273 3 2 3 3 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
274 3 1 1 1 1 1 MO 4 1 4 4.00 4.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
275 1 2 1 2 3 1 MO 1 2 4 0.00 0.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
276 3 2 3 3 3 1 MU 4 2 1 4.00 4.00 N E N 3.00 N C C NEG NEG NEG N NR NEG 4 5
277 1 2 2 3 4 2 MU 1 7 1 7.00 U N Y 3.00 Y P P MNG NEG NEG N NR NEG 5 8
278 3 2 3 2 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
279 2 2 3 1 3 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9






















































































































































































































































































































































281 3 1 3 2 3 1 MU 4 2 1 5.00 5.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
282 2 1 3 2 2 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
283 4 1 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
284 2 1 3 2 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
285 1 1 3 2 3 1 MO 2 2 4 3.00 3.00 N E P 1.00 N P NEG NEG NEG NEG N NR NEG 4 6
286 3 2 2 2 3 1 MO 4 7 4 3.00 3.00 U N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
287 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
288 3 1 3 2 4 5 MO 4 1 4 3.00 3.00 N E P 3.00 Y NEG Y NEG NEG NEG N NR POS 7 12
289 4 2 3 2 3 1 MO 4 1 4 4.00 4.00 N N P 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
290 2 2 3 2 1 1 MO 3 1 4 1.00 1.00 N E P 3.00 N C P NEG NEG NEG N NR NEG 4 5
291 1 1 3 2 3 1 MO 2 2 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
292 3 1 2 3 3 1 MU 3 12 1 3.00 3.00 G N N 2.00 N NEG P NEG NEG NEG N NR NEG 4 6
293 2 2 3 1 1 2 MO 1 1 4 0.00 0.00 N N N 3.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
294 3 1 3 2 1 2 MO 1 5 4 0.00 0.00 S N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 7
295 2 2 5 2 1 2 MU 1 3 4 0.00 0.00 N N N 2.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
296 1 2 3 3 2 3 MU 1 1 1 3.00 3.00 N N N 3.00 N C C NEG NEG NEG N R,1DIL NEG 6 5
297 2 2 3 1 3 4 MO 1 4 4 1.00 1.00 N D N 3.00 N NEG P NEG NEG NEG N NR NEG 4 5
298 3 1 2 1 1 4 MU 2 2 2 0.00 0.00 N E N 2.00 Y NEG P NEG NEG NEG N NR NEG 4 6
299 1 2 5 2 1 1 MO 3 5 4 2.00 2.00 N N N 2.00 N C NEG NEG NEG NEG N NR NEG 8 5
300 3 2 3 3 1 1 MO 4 1 4 3.00 3.00 N E P 2.00 N P P NEG NEG NEG N NR NEG 4 6
301 2 2 3 2 2 1 MO 2 1 4 3.00 3.00 N E P 3.00 N TV NEG NEG NEG NEG N NR NEG 8 2
302 2 2 1 1 4 2 MO 1 1 4 0.00 0.00 N N N 3.00 N P NEG NEG NEG NEG N NR NEG 4 9
303 1 1 1 3 3 2 MO 1 1 4 0.00 0.00 N D N 1.00 N TV NEG NEG NEG NEG P NR NEG 4 2
304 2 1 3 2 2 3 MO 3 3 4 2.00 2.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
305 3 2 5 1 1 1 MO 4 2 4 3.00 3.00 N N P 2.00 P NEG NEG NEG NEG NEG N NR NEG 4 5
306 3 2 3 3 3 1 MO 4 3 4 4.00 4.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
307 2 1 2 1 2 1 MU 3 2 1 4.00 4.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 2 6






















































































































































































































































































































































309 4 1 1 3 4 4 MO 1 10 4 0.00 0.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
310 2 2 3 2 2 5 MU 2 2 2 1.00 1.00 N E P 2.00 N C C NEG NEG NEG N NR NEG 4 5
311 2 1 1 1 1 5 MU 2 1 4 0.00 0.00 N E P 1.00 N P NEG NEG NEG NEG N NR NEG 4 6
312 1 2 2 1 2 2 MU 1 2 1 0.00 0.00 N E P 3.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
313 2 1 3 2 3 1 MO 1 1 4 1.00 1.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
314 3 2 3 3 3 1 MO 3 2 4 2.00 2.00 N E P 3.00 P P NEG NEG NEG NEG N NR NEG 4 6
315 1 2 2 1 3 1 MU 1 1 1 6.00 N N P 3.00 P C C NEG NEG NEG N NR NEG 4 6
316 4 1 1 1 1 1 MO 4 14 4 4.00 4.00 N N N 1.00 P NEG NEG NEG NEG NEG N NR NEG 4 9
317 3 1 3 2 2 1 MO 3 5 4 3.00 3.00 N E P 3.00 P NEG NEG NEG NEG NEG N NR NEG 4 6
318 2 2 5 2 3 1 MU 2 2 2 2.00 2.00 N E N 3.00 N NEG C NEG NEG NEG N NR NEG 4 5
319 3 2 3 2 2 1 MO 2 2 4 3.00 3.00 N N P 3.00 Y C C NEG NEG NEG N NR NEG 4 5
320 1 1 1 1 1 1 MU 1 4 1 1.00 1.00 N E P 1.00 N P NEG NEG NEG NEG N NR NEG 2 5
321 2 1 3 2 4 1 MO 2 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
322 2 2 3 1 3 1 MO 2 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
323 4 2 3 1 1 1 MO 4 2 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
324 3 2 3 1 1 1 MU 4 2 2 4.00 4.00 N N P 1.00 N NEG P NEG NEG NEG N NR NEG 4 2
325 4 2 1 1 1 1 MO 4 2 4 1.00 1.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
326 3 2 1 1 1 1 MO 3 5 4 2.00 2.00 S E P 3.00 N NEG P NEG NEG NEG N NR NEG 4 7
327 5 1 1 1 1 1 MO 4 2 4 2.00 2.00 N E P 2.00 N NEG P NEG NEG NEG N NR NEG 4 5
328 2 1 1 1 1 1 MO 1 1 4 2.00 2.00 N N 2 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 2
329 5 2 1 1 1 1 MU 4 7 2 3.00 3.00 U N N 3.00 N NEG NEG MNG NEG NEG N NR NEG 4 8
330 1 2 1 1 1 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
331 2 2 1 1 1 1 MO 3 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
332 3 2 3 1 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 9
333 1 2 1 1 2 1 MO 1 1 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
334 3 1 1 2 3 1 MO 4 1 4 3.00 3.00 N D P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
335 3 2 1 1 2 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9






















































































































































































































































































































































337 2 1 3 1 3 1 MO 4 2 4 3.00 3.00 N E P 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
338 2 1 1 1 4 1 MO 3 2 4 2.00 2.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
339 2 2 3 1 3 1 MO 1 2 4 1.00 1.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
340 2 1 3 2 2 1 MO 4 1 4 3.00 3.00 N E N 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
341 2 1 3 3 3 1 MO 3 2 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
342 2 1 3 2 2 1 MU 1 2 1 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 3
343 1 2 3 3 3 1 MO 2 9 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 2 9
344 3 2 3 3 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
345 3 1 1 1 1 1 MO 4 1 4 4.00 4.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
346 1 2 1 2 3 1 MO 1 2 4 0.00 0.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
347 3 2 3 3 3 1 MU 4 2 1 4.00 4.00 N E N 3.00 N C C NEG NEG NEG N NR NEG 4 5
348 1 2 2 3 4 2 MU 1 7 1 7.00 U N Y 3.00 Y P P MNG NEG NEG N NR NEG 5 8
349 3 2 3 2 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
350 2 2 3 1 3 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
351 3 1 3 3 2 1 MO 2 8 4 0.00 0.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
352 3 1 3 2 3 1 MU 4 2 1 5.00 5.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
353 2 1 3 2 2 1 MO 2 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
354 4 1 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
355 2 1 3 2 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
356 1 1 3 2 3 1 MO 2 2 4 3.00 3.00 N E P 1.00 N P NEG NEG NEG NEG N NR NEG 4 6
357 3 2 2 2 3 1 MO 4 7 4 3.00 3.00 U N P 1.00 N NEG NEG NEG NEG NEG P NR NEG 4 2
358 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
359 3 1 3 2 4 5 MO 4 1 4 3.00 3.00 N E P 3.00 Y NEG Y NEG NEG NEG N NR POS 7 12
360 4 2 3 2 3 1 MO 4 1 4 4.00 4.00 N N P 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
361 2 2 3 2 1 1 MO 3 1 4 1.00 1.00 N E P 3.00 N C P NEG NEG NEG N NR NEG 4 5
362 1 1 3 2 3 1 MO 2 2 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
363 3 2 3 2 4 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9






















































































































































































































































































































































365 3 1 1 2 3 1 MO 4 2 4 2.00 2.00 N E N 3.00 N NEG P NEG NEG NEG N NR NEG 4 6
366 2 2 1 2 2 1 MO 1 4 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
367 3 1 3 1 3 1 MO 4 11 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
368 3 2 1 1 1 1 MO 4 1 4 0.00 0.00 N D N 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
369 2 2 3 1 2 1 MO 3 11 4 2.00 2.00 N N N 3.00 N NEG P NEG NEG NEG N NR NEG 4 9
370 2 2 5 1 2 1 MO 3 1 4 1.00 1.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
371 2 1 3 3 3 1 MO 4 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
372 1 2 2 3 3 1 MO 1 2 1 7.00 N D C 3.00 N C P NEG NEG NEG N NR NEG 4 5
373 3 2 2 2 2 1 MO 4 1 4 4.00 4.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
374 5 1 3 1 3 1 MO 4 2 4 4.00 4.00 N G P 2.00 N NEG P NEG NEG NEG N NR NEG 4 2
375 1 2 1 1 3 1 MO 1 8 4 0.00 0.00 N N N 3.00 N NEG P NEG NEG NEG N NR NEG 4 5
376 1 2 3 2 3 1 MO 1 2 4 0.00 0.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
377 3 2 3 2 4 5 MO 4 11 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
378 2 1 3 2 4 1 MO 3 2 4 2.00 2.00 N N P 3.00 N NEG P NEG NEG NEG N NR POS 4 3
379 2 1 1 2 4 1 MO 3 5 4 2.00 2.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
380 2 2 3 2 3 1 MO 3 9 4 2.00 2.00 N N P 2.00 Y NEG NEG NEG NEG NEG N NR NEG 4 4
381 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
382 2 2 5 2 3 1 MO 4 5 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
383 1 1 5 2 3 1 MO 2 5 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
384 1 2 3 3 3 1 MO 1 2 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
385 2 1 3 1 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
386 4 2 3 2 4 1 MO 4 11 4 1.00 1.00 N N N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
387 4 2 3 2 4 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
388 2 1 1 1 1 1 MO 3 1 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
389 1 2 4 3 4 1 MO 1 5 4 0.00 0.00 S N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
390 2 1 3 2 4 1 MO 4 2 4 2.00 2.00 N E P 3.00 N C C NEG NEG NEG N NR NEG 4 5
391 1 1 1 1 1 1 MO 2 3 4 1.00 1.00 N E C 3.00 N NEG C NEG NEG NEG N NR NEG 4 6






















































































































































































































































































































































393 2 2 2 3 3 5 MU 1 2 4 3.00 3.00 N E N 3.00 N NEG P NEG NEG NEG N NR NEG 4 6
394 1 2 2 3 3 2 MU 1 1 1 0.00 0.00 N N N 3.00 N C NEG NEG NEG NEG N NR NEG 5 5
395 1 2 2 3 3 2 MU 1 1 4 6.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 5 10
396 1 2 2 3 4 2 MU 1 2 1 0.00 0.00 N N P 3.00 N TV P NEG NEG NEG P NR NEG 5 2
397 1 1 2 2 4 1 MU 1 2 1 2.00 2.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 6 5
398 1 1 3 2 3 1 MU 2 1 2 0.00 0.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 6 10
399 2 2 2 2 3 1 MU 4 1 2 2.00 2.00 N E P 2.00 N P P NEG NEG NEG N NR NEG 4 6
400 1 2 2 2 3 4 MU 2 1 2 1.00 1.00 N N N 3.00 Y C C NEG NEG NEG N NR NEG 5 5
401 2 2 1 2 3 1 MO 4 11 4 3.00 3.00 N N 2 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
402 2 1 2 3 2 1 MU 2 1 2 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 7 3
403 2 2 2 2 3 1 MU 3 12 1 0.00 0.00 G E P 3.00 N NEG P NEG NEG NEG N NR NEG 7 12
404 2 2 3 2 3 1 MO 1 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
405 5 2 3 2 2 5 MO 4 1 4 1.00 1.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 9
406 4 2 1 1 1 1 MO 4 2 3 2.00 2.00 N E P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
407 1 1 1 1 1 1 MO 1 1 4 0.00 0.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
408 4 1 1 1 1 1 MO 4 4 2 4.00 4.00 N G P 1.00 Y NEG NEG NEG NEG NEG N NR POS 7 12
409 1 2 3 1 4 1 MO 1 2 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
410 4 2 1 1 3 1 MO 4 2 4 3.00 3.00 N N N 1.00 N NEG Y NEG NEG NEG N NR NEG 4 3
411 2 1 3 2 3 1 MO 2 1 4 3.00 3.00 N N P 1.00 N NEG P NEG NEG NEG N NR NEG 4 3
412 2 1 1 1 1 1 MO 1 2 4 1.00 N E P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
413 1 2 1 1 3 1 MO 1 2 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 5
414 1 2 3 2 4 2 MO 1 1 1 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 5 9
415 2 1 5 1 3 1 MO 3 3 4 3.00 3.00 N D N 1.00 Y NEG NEG NEG NEG NEG N NR NEG 8 4
416 5 2 5 2 1 1 MO 4 1 4 2.00 2.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
417 2 1 1 1 3 1 MO 2 2 4 3.00 3.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
418 5 2 1 1 1 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
419 2 2 3 3 3 1 MO 1 9 4 0.00 0.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 1 6






















































































































































































































































































































































421 2 2 5 1 3 1 MO 2 1 4 2.00 2.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
422 3 1 5 2 1 1 MO 4 2 4 2.00 2.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
423 1 2 1 1 3 1 MO 3 1 4 3.00 3.00 N E P 1.00 N P P NEG NEG NEG N NR NEG 4 3
424 3 2 5 2 3 1 MO 4 1 4 2.00 2.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
425 2 1 1 1 1 1 MU 3 13 2 3.00 3.00 N E P 1.00 N NEG NEG NEG NEG NEG N NR NEG 6 10
426 5 2 5 2 3 5 MO 4 1 4 2.00 2.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
427 3 1 1 1 2 1 MO 4 2 4 3.00 3.00 N D P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
428 2 2 5 1 1 1 MO 4 1 2 2.00 2.00 N D N 1.00 N C C NEG NEG NEG N NR NEG 4 5
429 2 1 3 2 3 1 MO 2 2 4 0.00 0.00 N N N 1.00 N P P NEG NEG NEG N NR POS 7 12
430 3 2 3 2 2 5 MU 4 2 2 1.00 1.00 N E N 1.00 N P P NEG NEG NEG N NR NEG 4 6
431 5 2 3 2 2 5 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
432 3 1 3 2 3 1 MO 4 2 4 3.00 3.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
433 4 1 1 1 1 1 MO 4 1 4 5.00 5.00 N D P 1.00 N TV P NEG NEG NEG N NR NEG 4 5
434 2 1 5 3 2 1 MO 4 4 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
435 4 2 3 1 1 1 MO 4 1 4 2.00 2.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
436 2 2 5 1 1 1 MO 1 2 4 2.00 2.00 N N P 1.00 P NEG P NEG NEG NEG N NR NEG 4 3
437 1 2 1 1 3 1 MO 2 2 4 2.00 2.00 N N P 1.00 Y Y Y NEG NEG NEG N NR NEG 4 4
438 3 2 3 1 1 1 MO 4 9 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 6 10
439 4 2 2 1 1 1 MO 4 2 2 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR POS 4 12
440 3 1 3 1 2 1 MU 4 2 4 3.00 3.00 N N P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
441 4 1 1 1 1 1 MO 4 1 2 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
442 3 2 5 2 3 1 MO 4 1 4 2.00 2.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
443 1 2 3 3 3 1 MO 1 1 4 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
444 2 2 3 1 2 1 MO 2 2 4 3.00 3.00 N N N 1.00 N NEG P NEG NEG NEG N NR NEG 4 3
445 2 2 2 2 3 1 MO 3 1 4 3.00 3.00 N E N 1.00 Y NEG NEG NEG NEG NEG N NR NEG 4 6
446 2 1 3 2 3 1 MO 3 2 4 4.00 4.00 N N N 1.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
447 4 2 1 1 1 1 MO 4 2 3 2.00 2.00 N E P 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 6






















































































































































































































































































































































449 3 1 1 1 3 1 MO 3 1 4 3.00 3.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
450 3 2 3 1 3 1 MO 4 1 4 2.00 2.00 N D N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
451 3 2 3 1 3 1 MO 4 1 4 2.00 2.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
452 2 2 1 2 3 1 MO 3 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
453 1 2 3 2 4 2 MO 1 1 1 0.00 0.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 5 9
454 2 2 1 2 1 2 MU 1 2 4 2.00 2.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
455 4 1 1 1 1 1 MO 4 2 4 1.00 1.00 N D N 3.00 N C C NEG NEG NEG N NR NEG 4 5
456 2 1 3 1 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
457 2 2 3 1 1 2 MO 1 1 4 0.00 0.00 N N N 3.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
458 4 1 1 1 1 1 MU 4 1 1 4.00 4.00 N E P 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 13
459 2 1 5 1 2 1 MO 2 2 4 3.00 3.00 N D P 3.00 P NEG P NEG NEG NEG N NR NEG 4 6
460 4 1 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
461 2 2 1 1 1 1 MO 3 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG P NR NEG 4 1
462 3 2 1 1 1 1 MO 3 5 4 2.00 2.00 S E P 3.00 N NEG P NEG NEG NEG N NR NEG 4 7
463 2 1 3 2 2 1 MU 1 2 1 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
464 1 2 2 3 3 1 MO 1 2 1 7.00 N D C 3.00 N C P NEG NEG NEG N NR NEG 4 5
465 2 2 3 2 1 1 MO 3 1 4 1.00 1.00 N E P 3.00 N C P NEG NEG NEG N NR NEG 4 5
466 2 2 3 2 1 2 MO 3 9 4 2.00 2.00 N N N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
467 3 1 3 1 3 1 MO 4 11 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
468 1 1 1 1 1 1 MO 2 3 4 1.00 1.00 N E C 3.00 N NEG C NEG NEG NEG N NR NEG 4 6
469 2 1 3 2 2 1 MO 4 1 4 3.00 3.00 N E N 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
470 1 2 1 1 2 1 MO 1 1 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
471 2 1 1 2 3 1 MO 3 2 1 2.00 2.00 N N N 1.00 N TV NEG NEG NEG NEG N NR NEG 4 2
472 3 1 3 2 4 5 MO 4 1 4 3.00 3.00 N E P 3.00 Y NEG Y NEG NEG NEG N NR POS 7 2
473 2 2 1 1 1 1 MO 3 1 4 3.00 3.00 N D N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 1
474 1 2 2 3 4 2 MU 1 2 1 0.00 0.00 N N P 3.00 N TV P NEG NEG NEG N NR NEG 5 2
475 3 2 1 1 1 1 MO 3 5 4 2.00 2.00 S E P 3.00 N NEG P NEG NEG NEG P NR NEG 4 7






















































































































































































































































































































































477 2 2 1 2 2 1 MO 1 4 4 1.00 1.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
478 2 1 3 2 3 1 MO 4 1 4 3.00 3.00 N N N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
479 2 1 3 1 3 1 MO 4 2 4 3.00 3.00 N E P 3.00 N P NEG NEG NEG NEG N NR NEG 4 6
480 4 1 1 3 4 4 MO 1 10 4 0.00 0.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 3
481 3 2 3 2 4 5 MO 4 2 4 2.00 2.00 N D N 2.00 Y NEG Y NEG NEG NEG N NR NEG 4 4
482 2 2 5 3 3 1 MO 1 2 4 2.00 2.00 N E N 1.00 N NEG NEG NEG NEG NEG N NR NEG 4 2
483 4 1 1 2 3 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
484 3 2 3 1 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N P P NEG NEG NEG N NR NEG 4 9
485 1 2 1 1 1 1 MO 4 1 4 2.00 2.00 N E P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
486 3 2 3 2 4 1 MO 4 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
487 3 2 2 2 3 1 MU 3 1 4 3.00 3.00 N E P 3.00 N NEG NEG NEG NEG MNG N NR NEG 4 8
488 3 1 2 3 3 1 MU 3 12 1 3.00 3.00 G N N 2.00 N NEG P NEG NEG NEG N NR NEG 4 6
489 3 2 5 2 1 1 MO 4 1 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
490 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N P 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
491 2 1 3 2 2 1 MU 1 2 1 0.00 0.00 N N N 3.00 N C C NEG NEG NEG N NR NEG 4 5
492 2 1 1 2 4 1 MO 3 5 4 2.00 2.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
493 3 2 3 3 3 1 MO 3 1 4 2.00 2.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
494 1 2 5 2 2 1 MO 2 1 4 2.00 2.00 N N P 2.00 Y Y Y NEG NEG NEG N NR NEG 4 4
495 2 2 2 3 3 5 MU 1 2 4 3.00 3.00 N E N 3.00 N NEG P NEG NEG NEG N NR NEG 4 6
496 3 2 1 2 1 1 MO 4 1 4 3.00 3.00 N N N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 9
497 2 2 1 2 3 1 MO 3 2 4 3.00 3.00 N E N 3.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
498 1 2 2 3 4 2 MU 1 2 1 0.00 0.00 N N P 3.00 N TV P NEG NEG NEG N NR NEG 5 TV
499 1 2 1 1 3 1 MO 2 2 4 2.00 2.00 N N P 1.00 Y Y Y NEG NEG NEG N NR NEG 4 4
500 3 1 5 3 1 1 MO 4 1 4 1.00 1.00 N E N 2.00 N NEG NEG NEG NEG NEG N NR NEG 4 6
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MASTER CHART KEY WORDS 
Age(C)  
1.  18-25 
2.  26-35 
3.  36-45 
4.  >45 
Address(D)  
1.  Rural  
2.  Urban 
Occupation(E)  
1.  Coolie 
2.  CSW 
3.  House Wife 
4.  Others 
Monthly Income(F)  
1.  <5000 
2.  5001-10000 
3.  >10000 
Educational Status(G)  
1.  I lli terate 
2.  <5th Std 
3.  6t h -12th  
4.  Graduate 
5.  Professional  
Mari tal  Status(H)  
1.  Married 
2.  Unmarried 
3.  Separated 
4.  Divorced 
5.  Widow 
No. of Partners(I)  
Mo Mono 
MU Mul tiple 
 
Married Since(J)  
1.  < 5years 
2.  5-10 years 
3.  10-15 years 
4.  > 15 years 
Presenting Complaints(K)  
1.  Asymptomatic 
2.  Vaginal Discharge 
3.  Dysuria 
4.  Pain Abdomen 
5.  Others (Bartholin’s 
cyst)  
6.  Post Menopausal 
Bleeding 
7.  Genital Ulceration 
8.  Infertil ity 
9.  Contact Tracing 
10.  LBA 
11.  Itching Geni talia 
12.  Warty  Growth 
13.  TPHA +ve 
14.  Dysparunia 
 
Sexual History(L)  
1.  Pre-marital contact 
2.  Extra mari tal 
contact 
3.  Previous venereal 
disease 
Menstrual History(M) 
1.  R-Regular/ IR- 
Irregular 
2.  Abnormal blood loss 
3.  Post Coital bleeding 
4.  Menopause 
Obstetr ic History(N)  
A No.  of Children  
(1, 2,  3, 4)  
B OC Pil l s 
C Copper T 
D Barr ier Method 
E Permanent 
Sterili sation 
F No contraception 
Personal History(O)  
1.  IV Drug Abuse 
2.  Alcoholi sm 
3.  Smoking 
4.  Nothing Relevant 




Per  vaginal Examination 
(Discharge)(Q)  
1.  Curdy white 
2.  Greenish frothy 
3.  Profuse 
Homogenous 
4.  Normal  
5.  Bleeding PV 
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GS-Gram stain-(T),(X)  
P Pus Cell  
C Clue Cel l  
Y  Yeast (candida)  
2 Secondary 
Organisms 
PS-Pap smear-(U)  
1. Normal Pap-N 
2. Inflammatory smear-IS 
 IS (N) – Neutrophil s 
 IS (MN) - Monocytes, 
 Neutrophil s 
 IS (P) - Polymorphs 
3. Atypical squamous 
 cell s  – AT 
4. Low grade squamous 
intra epithelial l esion-
LSIL 
5. High grade squamous 
intra epithelial l esion-
HSIL 




8. Inadequate smear- IN 
9. Parabasal cell s-P 
 Vagina 
KOH- Potassium  
Hydroxide (V)  
CL Clue Cel l  
Y  Yeast Cell  
NS- Normal  Saline (W) 





DF Dark Field(Y)  
TZ Tzank Smear(Z)  
GS Gram Stain(AA) 
LS Leishman Stain(AB)  
 
Gonococcol cul ture(AC)  
P Positive 
N Negative 







HIV ab (AF)  
P Positive 
N Negative 
Spouse Assessment (AG) 
1.  Genital Ulcer 
2.  Genital / Urethral 
Discharge 
3.  Bubo 
4.  Not done 
5.  Not applicable 
6.  Syphilli s 
7.  HIV 
8.  Balanoposthiti s 
9.  Genital Wart 
Hep.B & Hep.C (AH) 
P Positive 
N Negative 
DIAGNOSIS (AI)  
1.  Lower abdominal pain 
2.  Trichomonas vaginals 
3.  VD (Vaginal discharge)  
4.  Candidiasis 
5.  Bacter ial vaginosis 
6.  Cervici ti s 
7.  Barthol in’s Cyst 
8.  Herpes Simplex 
9.  NV (Non Venereal )  
10.  Syphili s 
11.  Genital warts 
12.  HIV 
13.  Others 
